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1. The Pharmaceutical Society of Ireland (PSI) commissioned Horwath Bastow Charleton (HBC) in 
late 2009 to conduct a study to provide an understanding of the nature and type of pharmacy 
services currently being delivered in Ireland, and to review and report on the international profile 
of the standards of pharmacy service and care delivery.  
2. The first phase of the study was intended to focus on the provision of core and extended 
pharmacy services in Ireland, providing baseline information for the PSI to enable it to 
understand the nature and scope of pharmacy provision nationally, to identify strengths and 
weaknesses in the sector, and to develop future policy to improve and implement change for 
pharmacy provision in Ireland. 
3. The second phase was designed to be an international review study, examining pharmacy 
provision and regulation in other EU countries, Australia, Canada, New Zealand and other 
countries as identified, seeking to identify and analyse the nature and scope of pharmacy 
provision, best practice, policies and practice in relation to performance management, and how 
pharmacy provision fits within the wider health and social care sector in each comparator 
country. 
4. It was agreed with the Steering Group and PSI to carry out the data collection in two ways: 
 A census survey of all community pharmacies (that is, 100% of the population) collecting 
structured data on pharmacy activity, staffing, infrastructure, etc; 
 A follow-up interview with approximately 40 community pharmacies across the country, 
examining more qualitative issues in relation to the future development of pharmacy 
services, areas in which pharmacists would like to see change, inter-professional 
relationships, CPD, and so on. 
5. The total response rate (457 surveys) is 28% (not including incomplete submissions), which 
gives us a good margin over the agreed target of 20% necessary to have confidence in the 
results. 
6. The main findings relating to the profile of the pharmacists completing the survey (Section 2 of 
our report) are as follows: 
 more than 83% of respondents held the role of Supervising Pharmacist or both Supervising 
and Superintendent Pharmacist; 
 45% of respondents were the pharmacy owner, and just over 26% were the manager; 
 59% responded that they had been working in the pharmacy for more than five years; 
 the average (mean) hours worked by respondents in a typical week was 42.6, with the most 
common response (mode) being 40 hours per week; 
 51.4% of respondents were female and 46.4% were male, with just over 2% failing to 
answer the question; 
 almost 39% of respondents were aged under 35, with 35% being aged between 35 and 44; 
 profile of pharmacists and pharmacies completing survey is representative of profile of the 
PSI‟s register;  
 the average length of time registered as a pharmacist was more than 15 years, with the 
most common response being 10 years – responses ranged from 2 to 53 years; 
 37% of respondents undertook their degree at TCD, 43% at UCD, and the remainder at 
other Irish, UK or international colleges; 
 99.8% of respondents reported that they had practised in community pharmacy, 23.4% 
indicated they had undertaken hospital pharmacy, 5.8% had worked in industry, and another 
4.5% in research. 
7. The main findings relating to the services provided by pharmacists completing the survey 
(Section 3 of our report) are as follows: 
 26.5% of respondents had prescription dispensing numbers in excess of 5,000 per month; 
 GMS prescriptions represent the largest numbers for pharmacies‟ dispensing activity; 
 32.7% of respondents provide services to residential care settings; 
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 The top three services not currently provided, but which pharmacists would like to provide in 
future, consist of Lung Capacity Screening, Sexual Health, and Structured Medicine Use 
Reviews; 
 Pharmacists spend most of their professional time during normal working hours on 
dispensing prescription medicines, counselling prescription patients, counselling non-
prescription patients, and giving advice about minor illness; 
 Pharmacists spend most of their professional time outside normal working hours on CPD 
activities, attending health-related meetings and audit and practice research; 
 The appetite for providing enhanced pharmacy services in future was mixed. Overall, the 
majority of those we spoke to were keen to provide enhanced services such as health 
promotion programmes (e.g. weight loss or smoking cessation), and screening, diagnostic 
and monitoring services like blood pressure measurement, blood sugar testing for diabetes, 
cholesterol levels, and Warfarin levels;  
 However, there are many who believe that the key skills of pharmacists remain with 
medicines expertise and core dispensing of prescription and OTC medication; 
 The main barrier to providing enhanced pharmacy services was identified as being money. If 
pharmacies had a different income model, the interviewees suggested, one that generated 
income for all the services provided, then they could pay for more qualified staff, which in 
turn would free up the time of the supervising pharmacist and others to develop and run 
these enhanced services; 
 Other potential barriers included opposition by local GPs and other healthcare providers to 
the extension of diagnostic or treatment services to pharmacy, and the availability of 
specific, validated training in clinical procedures. 
8. The main findings relating to the use of information technology by the pharmacists completing 
the survey (Section 4 of our report) are as follows: 
 The vast majority of pharmacists were entirely happy with their current IT infrastructure; 
 Some expected that significant changes would be required to their current systems, but, for 
many, any changes to accommodate new services would be relatively minor – add-ons or 
upgrades rather than complete new systems; 
 Many pharmacists stated that they would like their IT system to support interventions in 
relation to supply of non-prescription medicines, referrals, provision of specific advice and 
other professional and clinical interventions not currently regularly recorded; 
 Many pharmacists felt that access to at least some patient data held by GPs and others 
would be helpful to their practice. 
9. The main findings relating to the inter-professional relationships between the pharmacists 
completing the survey and other healthcare professionals (Section 5 of our report) are as follows: 
 The majority of pharmacists were either satisfied (32.2%) or very satisfied (28.2%) with the 
relationship with local doctors; 
 94.6% of those who responded said they did not have engagement with local multi-
professional groups; 
 91.6% of pharmacists indicated they had no engagement with patient support groups; 
 Most pharmacists‟ main relationship is with the local GPs, and for the majority of 
pharmacists whom we interviewed, this relationship is very good. In general, interviewees 
felt their interactions with their GPs were cordial, that the relationship involved mutual 
respect, that the communication was good, and that they could work together for patients‟ 
benefit. 
10. The main findings relating to the workforce (Section 6 of our report) are as follows: 
 On average, there were 2 pharmacists reported as working in each pharmacy (the maximum 
reported number of pharmacists was 5); 
 The average number of pharmaceutical assistants was 0.7 per pharmacy, with 1 being the 
most common answer;  
 The average number of pharmacy technicians was 1.4 per pharmacy;  
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 The average number of counter staff was 3 per pharmacy, and other staff averaged 1.3 per 
pharmacy; 
 When asked what, if anything, they would change about the workforce in the pharmacy, 
most pharmacists responded that they would take on more staff, in an ideal (i.e. affordable) 
situation. For most, they would like to take on more qualified pharmacists, usually a full-time 
second pharmacist for single-pharmacist pharmacies; 
 Almost all interviewees identified that they would like a better ratio of pharmacists to other 
staff, with the likelihood that this could provide potential improvements in services to 
patients, such as more time to spend counselling, and the ability to develop new services; 
 Pharmacists were also very enthusiastic about the benefits arising from working alongside 
another professional pharmacist: almost everyone felt that this improved or would improve 
their own professional practice by challenging them and highlighting and filling in gaps in 
their own knowledge. 
11. The main findings relating to continuing professional development/continuing education 
(Section 7 of our report) are as follows: 
 A significant majority of pharmacists undertake formal and informal CPD/CE activities: 
76.1% list attendance at ICCPE lectures and 90.8% state that they read professional 
journals, while 66.7% said that their CPD/CE activities included addressing learning 
opportunities in their everyday practice; 
 Fewer than half of pharmacies pay for membership of ICCPE, or provide in-house training 
and development; 
 Over 60% of pharmacists responding to the survey stated that enablers to better uptake of 
CPD/CE would include availability closer to their pharmacy, greater frequency/more 
convenient times, an enhanced range of topics, or online/technology-based learning; 
 The most commonly-identified barrier to CPD/CE for 83.9% of pharmacists was lack of time; 
 Amongst pharmacists whom we interviewed, there was quite a varied opinion on the quality 
of the CPD and CE activities provided by the ICCPE; some pharmacists were quite happy 
with the content and the range of topics covered, while others rated the quality of the 
content as low and were unhappy with the information presented and how it was delivered; 
 Many of those interviewed undertake their own CPD and CE activities, often using online 
resources. Several suggested that the ICCPE should expand into online CPD and CE 
provision to address the issues surrounding access and time; 
 There was near-universal agreement that future service development, especially into 
screening and diagnostic services, would require specific CPD and CE resources to support 
this.  
12. The main findings relating to premises and setting (Section 8 of our report) are as follows: 
 Just over half of the respondents were in single-outlet pharmacies (52%), with small group 
or chain pharmacies representing 26.3% of the responses and large group or chain 
pharmacies representing 21.7%; 
 The average length of time that pharmacies in the survey were established was 32.8 years, 
with a maximum of 161 years and a minimum of 0.08 years; 
 On average, older patients made up 60% of respondents‟ patient profiles, with families with 
young children representing 26.7%, younger patients (12-30) making up 16.2%, and 
patients in residential care 5.4%. Pharmacists indicated that repeat or regular patients make 
up 78% on average of the pharmacy patient profile; 
 In terms of future service provision, many respondents felt that their premises were 
adequate, especially with the consultation area in place. Others felt that further expansion or 
improvement would be necessary, especially in relation to specific aspects such as sterile 
conditions for certain diagnostic or monitoring procedures. The existing consultation areas 
would be too small in some pharmacies to accommodate equipment for some screening and 
diagnostic procedures. 
13. Other main findings relating to strategic and overarching themes within community pharmacy 
(Section 9 of our report) include the following: 
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 Many respondents felt that the pharmacist is currently under-utilised and that there is 
potential to expand the role of pharmacy in healthcare services to patients. Screening and 
diagnostic services, medicine use reviews, minor ailment schemes, vaccinations, etc, are 
suggested as ways for the pharmacist to contribute more to patient care; 
 Related to this is the perception that pharmacy is under-valued and under-appreciated in the 
current healthcare structure; 
 There were many comments describing the sense that the regulatory environment has 
become very pressurised and many perceive the regulations as excessive and 
unnecessary. This is exacerbated by the increasing burden of administration relating to 
reimbursement for patient services from the State. Some are concerned that the paperwork 
requirements are taking from the time for patient care; 
 Many of the comments from pharmacists referred to a time of intense pressure on pharmacy 
and pharmacists. Financial pressure and the difficulties in the relationship with the State 
feature strongly. There is uncertainty among many pharmacists as to how things will 
develop, making it difficult for them to plan and have stability; 
 Several respondents indicated a desire to see closer integration of pharmacy into the 
primary healthcare structure, working more closely with GPs and other healthcare providers 
in a multi-disciplinary team set-up; 
 There was a very wide range of opinion in relation to the PSI‟s current role and activities, 
and some unhappiness expressed with how the PSI has taken up its role as regulator. 
14. Some of the key strategic issues to emerge from this research (Section 10 of our report) have 
included the following: 
 A key factor that emerged in relation to pharmacists' opinions on how pharmacy should 
develop was the common perception that there is no national vision for pharmacy and how it 
could and should fit into the wider healthcare delivery system. This is something which the 
PSI could be seen to address by continuing to work closely with the HSE and Department of 
Health and Children; 
 It would be worthwhile to examine ways to address the appetite for the provision of 
enhanced services, especially screening and diagnostic services, given the substantial body 
of positive responses to the "Would Like to Provide" questions for these services; 
 Further examination of the issue of medicines use reviews and pharmacist prescribing 
schemes may be merited, given their prominence in both the survey (80% would like to 
provide MURs) and the interviews, where both of these issues were key themes in what 
pharmacists want to see in community pharmacy in the future; 
 When looking at the development of further services, it would be helpful to take into account 
the influencing factors identified in our analysis and to focus on ways to encourage the 
provision of enhanced pharmacy services by those who are currently under-represented in 
the provision of, or appetite to provide, such services; 
 The PSI might consider looking at how it can support pharmacists in developing new 
services.  Potential mechanisms include the development of standards, the design of 
specific training programmes, and credentialing and privileging of "specialist" pharmacists or 
pharmacies to ensure that enhanced services are delivered according to specified 
standards; 
 Some of the data contained in this report has been superseded by the imminent 
development of, for example, mandatory CPD requirements and the establishment of the 
Institute of Pharmacy which will manage the new CPD system and also support the 
development of pharmacy practice; readers will therefore note that some of the data 
reported herein is now historical, and the PSI will no doubt wish to consider our findings as 
part of the implementation of these new arrangements. 
15. We recommend that there would be considerable merit for the PSI to repeat this survey (both 
quantitative and qualitative) in 2015, to track any changes which have occurred in the intervening 
4 years, so that trends can be identified, changes in practice and perception tracked, and the 
impact of interventions or initiatives assessed. 
 






The Pharmaceutical Society of Ireland (PSI) commissioned Horwath Bastow Charleton (HBC) 
in late 2009 to conduct a study to provide an understanding of the nature and type of 
pharmacy services currently being delivered in Ireland, and to review and report on the 
international profile of the standards of pharmacy service and care delivery. HBC was 
assisted in this project by Webstar Health, a specialist pharmacy consultancy in the UK, and 
by senior academic pharmacists in the University of Central Lancashire (UCLan). 
 
The first phase of the study was intended to focus on the provision of core and extended 
pharmacy services in Ireland, providing baseline information for the PSI to enable it to 
understand the nature and scope of pharmacy provision nationally, to identify strengths and 
weaknesses in the sector, and to develop future policy to improve and implement change for 
pharmacy provision in Ireland. 
 
The second phase was designed to be an international review study, examining pharmacy 
provision and regulation in other EU countries, Australia, Canada, New Zealand and other 
countries as identified, seeking to identify and analyse the nature and scope of pharmacy 
provision, best practice, policies and practice in relation to performance management, and 
how pharmacy provision fits within the wider health and social care sector in each comparator 
country. 
 
1.2 TERMS OF REFERENCE 
 
The PSI required the preparation of a survey questionnaire to be issued to all pharmacies. 
The objective of the survey was to collect information on the core/basis and extended/ 
additional pharmacy services in Ireland, including but not limited to the following: 
 Pharmacy and staff profiles; 
 Education and continuing education activities undertaken by registered pharmacists and 
other staff; 
 Prescription medicines-related activities, including but not limited to:  
o Residential Home Supply; 
o Monitored Dosage System use and supply; 
o Methadone dispensing;  
o Fertility treatment dispensing; 
 Non-prescription medicines related activities; 
 Medication review processes; 
 Type and nature of additional pharmacy services provided e.g. delivery services;  
 Barriers identified to the provision of additional pharmacy services; 
 Information facilities provided; 
 Health Screening Services including but not limited to:  
o Weight management clinics;  
o Point of care testing e.g. diabetes, cholesterol, pregnancy; 
o Harm minimisation services e.g. smoking cessation; 
o Alternative or complementary medicines. 
 
The second phase (international comparative review, report and analysis) was intended to 
assess available robust information for other countries on the parameters identified above. 
 
During the course of the project, we had an ongoing and very productive process of 
engagement with the PSI and the Steering Group established to oversee the study. This 
resulted in certain agreed changes being made to the approach and the timescales, all of 
which are reflected in this final report.  
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1.3 METHOD OF APPROACH 
 
It was agreed with the Steering Group and PSI to carry out the data collection in two ways: 
 A census survey of all community pharmacies (that is, 100% of the population) 
collecting structured data on pharmacy activity, staffing, infrastructure, etc; 
 A follow-up interview with approximately 40 community pharmacies across the country, 
examining more qualitative issues in relation to the future development of pharmacy 
services, areas in which pharmacists would like to see change, inter-professional 
relationships, CPD, and so on. 
 
The census survey was designed to be administered by a mix of a web-based survey and a 
paper-based version; pharmacies were encouraged to complete the survey online if they had 
the capability to do so, but had the option to complete the paper version if not. 
 
We engaged expert input from Dr John Newell, a biostatistician at NUI Galway, in order to 
ensure validity and accuracy of the statistical aspects of the research. 
 
Follow-up interviews were conducted in the majority of instances by phone, with a small 
number being undertaken in face-to-face interviews. 
 
The survey data was collated using SPSS, and the qualitative interview data by NVivo 
qualitative analysis software, with the overall information (facts, findings, analysis) compiled 
into this Emerging Findings report for the consideration of the Steering Group. 
 




Following an extensive preparatory period which involved significant engagement with the 
Steering Group, the quantitative survey commenced in late June 2010, with an initial deadline 
of 16 July 2010. Emails were issued to pharmacists inviting them to participate using 
individual tokens (passwords) to access the online survey. Paper versions were issued to 
those who could not be contacted by email and those who requested hard copies. A total of 
146 paper surveys were issued at this stage. The paper version of the survey is attached as 
Appendix 1. 
 
1.4.2 Response Rate 
 
The total response rate (457 surveys) is 28% (not including incomplete submissions), 
which gives us a good margin over the agreed target of 20% necessary to have confidence in 
the results. 
 
The geographic breakdown in late July indicated that some counties were under-represented. 
It was decided to target the counties with the lowest response rates, i.e. those with lower than 
15% response rates, and to send out paper versions to those pharmacies in each of the 
relevant counties (Carlow, Cavan, Laois, Limerick, Louth, Roscommon, Sligo, and 
Westmeath) who had not already completed the survey. 
 
A total of 220 paper surveys were issued to the targeted counties, improving the response 
rate considerably in most of the target areas: all counties now have a response rate of 15% or 
higher and only two counties (Longford and Roscommon) fall below a 20% response rate. 
 
1.5 QUALITATIVE INTERVIEWS 
 
The project interviewed community pharmacists to gain more insights about the issues 
covered in the survey. It was anticipated that it would be possible to reach data saturation (i.e. 
no new themes emerging) with participation from approximately 40 pharmacists. We 
conducted 40 interviews and are confident that we have captured the full range of opinion 
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from pharmacists, with the latter interviews clearly covering similar themes to those discussed 
in earlier consultations. 
 
Recruitment: Pharmacists who completed the survey were asked if they would be happy to 
undertake a follow-up interview. A final question was included in the survey, both online and 
paper versions (text below).  
 
We plan to interview approximately 30 pharmacists following this survey, in order to 
explore emerging issues in more detail. If you would be happy for an interviewer to 
contact you with more information about the interview, please put your name and 
preferred telephone/fax contact number here. This personal information will not be 
reported with the survey data. 
 
[Fields for name and telephone/fax number] 
 
If you do not hear from us by [put appropriate date here], then thank you for your 
interest but an interview will no longer be necessary. 
 
Approximately 90 pharmacists had agreed to be contacted in this way, giving us ample 
opportunity to reach our target interview figures. 
 
Volunteers were followed up by phone and interviews arranged. Participants were sent 
information sheets and returned consent forms by fax or email; alternatively, they verbally 
consented to participate at the outset of the interview.  
 
A semi-structured interview topic guide was prepared (attached as Appendix 2). Most 
interviews were conducted along this basic structure, sometimes altering the order in which 
sections were discussed, following the lead of the interviewee, sometimes encouraging 
interviewees to expand on certain areas or omitting irrelevant questions if appropriate to the 
specific pharmacist being interviewed. 
 
We conducted a small number of pilot interviews, set up as a teleconference so that one of 
the UCLan team could listen in and debrief with the interviewer. One question – which related 
to payment for technological data transfer – was dropped as it did not make sense in the 
context of the interview. 
 
The recordings were passed to our secretarial team for verbatim transcription. The 
HBC/UCLan team checked and anonymised the transcripts. Each transcript has an 
anonymised participant code. Each recording will be stored securely until the end of the 
project and then erased. 
 
We used a framework approach to analysis that was heavily informed by the domains we 
identified and the questions we asked. 
 
1.6 INTERNATIONAL LITERATURE REVIEW 
 
1.6.1 Scope of the International Literature Review 
 
The terms of reference for the Baseline Study issued by the PSI required us to compare the 
results of the survey with past work in pharmacy in countries with similar contexts. These 
countries were originally identified as Australia, Canada, Great Britain, New Zealand and 
South Africa. This element of the literature review was rescheduled to an earlier part of the 
project in order to inform the development of the online survey of pharmacists. 
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1.6.2 Framework Development 
 
Discussion between the members of the review team, drawing on their experience of similar 
surveys in pharmacy in England, resulted in the implementation of a framework within which 
we could describe the common elements of the papers that were included. The domains are:  
 premises;  
 workforce;  
 services;  
 CPD/education;  
 inter-professional relations; and  
 technology.  
 
This framework also reflected the content of the PSI scoping documents, and the first draft of 
the pharmacy survey. 
 
1.6.3 Strategy for Finding Comparator Papers 
 
We recognised that the outputs for similar pharmacy projects were as likely to be reports 
lodged on organisational websites as peer-reviewed publications. We took a pragmatic 
approach to the review that would explore both types of publication. 
 
We used a broad search term – „community pharmacy services survey‟ – in two major internet 
search engines – Google UK and Bing UK – and then examined the summary of each item on 
the first ten pages of results for each engine. If the summary looked relevant, we followed the 
link and examined each paper. Inclusion criteria were:  
 published since the year 2000;  
 English language;  
 community pharmacy focus;  
 survey or interview methodology;  
 community pharmacists and/or commissioners of services as respondents.  
 
Patient surveys about community pharmacy were not included. 
 
We also searched the International Journal of Pharmacy Practice and International Journal of 
Clinical Pharmacy (formerly Pharmacy World and Science) online archives (2003-2010) using 




We approached professional organisations and selected pharmacy schools by email in 
Australia, Canada, New Zealand, South Africa and the US
2
. Responses resulted in the 
identification of two further publications of interest, a reference to a document we had already 
found, and a response from New Zealand that they too would be publishing a review of 
enhanced services next year. 
 
Nineteen relevant outputs were identified. We found that the majority of publications were 
represented in the search results of both engines. A summary of the included outputs is 
below: 
 6 reports and 13 peer-reviewed publications (some of which could be linked back to an 
underpinning report); 
 Outputs from different countries as anticipated; 
o Australia (6), Canada (2), England/Wales (2), Other Europe (3), USA (6) 
                                                 
1
  Second search strategy, truncated from „community pharmacy services survey‟ as this only retrieved 20 items, none of 
which were relevant to the search. 
2
  American Association of Colleges of Pharmacy; Australian College of Pharmacy Practice and Management; 
Pharmaceutical Society of Australia; Canadian Pharmacists Association; Pharmaceutical Society of New Zealand; 
Pharmaceutical Society of South Africa.  
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 Some outputs covered a number of domains – others were more focused (see table 
overleaf in Section 1.8). 
 
1.7 STRUCTURE OF THE REMAINDER OF THIS REPORT 
 
The report is structured along the key themes or domains identified during the project as the 
main areas of interest both from the perspective of the PSI and the Steering Group and from 
the international research findings. 
 
We introduce the survey findings by looking at the key statistics relating to the profile of the 






 Continuing Professional Development and Continuing Education; 
 Inter-professional Relationships; 
 Overall Themes from Survey and Interviews. 
 
The last category arose during the course of our research and represents the views in relation 
to overarching themes expressed in the opinion questions in the survey and during the course 
of the interviews. A key element relates to the organisations impacting on pharmacy practice 
in Ireland: the PSI, the IPU, the HSE, the Department of Health and Children, and so on. 
 
Within each domain, we have presented the findings from the quantitative questionnaire and 
the qualitative interviews, and any relevant illustrative material from international research. 
 
These findings then lead us to our Conclusions and Recommendations to the PSI in respect 
of the research. 
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1.8 SUMMARY OF OUTPUTS RETRIEVED AND THE DOMAINS IN WHICH THEY HAVE USEFUL COMPARATOR INFORMATION 
 
Table 1: Outputs from International Review 
Output Premises Workforce Services CPD/education Inter-
professional 
Technology 
ACT Pharmacy Guild of Australia  X X X    
Berbatis et al. 2003 (AUS) X X X X X X 
Berbatis et al. 2007 (AUS) X X X X X X 
Blenkinsopp et al. 2007 (UK) X X X X X X 
Bradley et al. 2006 (UK)   X    
Doucette et al. 2006 (USA) X X X   X 
Feletto et al. 2010 (AUS) X X X X X X 
Gadkari et al. 2009 (USA) X X X    
Hansen et al. 2006 (USA)   X    
Hughes et al. 2010 (Europe) X X X X   
Management Committee, CPhA 2008 (Canada) X X X X X X 
McKesson 2008 (Canada) X X X  X  
Peacock et al. 2007 (USA) X X X X X  
Radford et al. 2009 (USA)   X    
Roberts et al. 2006a (AUS) X X X X X X 
Roberts et al. 2006b (AUS) X X X X X X 
Skrepnek et al. 2007 (USA) X X     
Westerling et al. 2010 (Finland)  X    X 
Zardain et al. 2010 (Spain)  X X X X X 
 
These papers are explored in more detail, including a summary of methods and response, in Appendix 3. 
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One questionnaire was completed per pharmacy, and we requested that this be completed by 
the Supervising Pharmacist where possible, or by the Superintendent Pharmacist if needs be. 
The following sections outline the profile of the pharmacists completing the survey. 
 
2.2 ANALYSIS OF DATA 
 
2.2.1 Designated Role 
 
The vast majority (more than 83%) of respondents held the role of Supervising Pharmacist or 
both Supervising and Superintendent Pharmacist. Those who were Superintendent but not 
Supervising Pharmacists comprised nearly 16% of responses, with a very small number who 
did not specify their role. 
 
Figure 1: Designated Role 
 
 
2.2.2 Position in Pharmacy 
 
When looking at the position in the pharmacy of the respondents, we found that nearly half 
(45%) of them were the pharmacy owner, just over 26% were the manager, and just under 
25% were another permanent employee, with nearly 4% categorising themselves as “Other”. 
 
 PSI Baseline Study Final Report 
8 
Figure 2: Position in Pharmacy 
 
 
Those ticking the “Other” category expanded on this: several were both owners and 
managers, many were part-owners, directors, or partners in the pharmacy, and some were 
managers of one aspect of the pharmacy but not the overall business manager. 
 
2.2.3 Length of Time Working in the Pharmacy 
 
We asked the responding pharmacists to indicate how long they had been working in this 
particular pharmacy. Well over half (59%) responded that they had been working in the 
pharmacy for more than five years, with the next largest response (21%) indicating that they 
had worked for between three and four years in that pharmacy. 
 
Figure 3: Length of Time Working in this Pharmacy 
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2.2.4 Hours Worked in a Typical Week 
 
Pharmacists were asked to outline their typical working hours on a weekly basis. The average 
(mean) hours in a typical week for the respondents was 42.6, with the most common 
response (mode) being 40 hours per week. The range was 4-90 hours. The following graph 
shows the distribution of responses to this question. 
 
Figure 4: Hours Worked in a Typical Week 
 
 
2.2.5 Other Pharmacy-Related Activity 
 
We asked participants to indicate if they undertook pharmacy-related activity other than their 
work in the pharmacy in question. More than 77% of those who responded to this question 
stated that they did not undertake such activity, with 22.6% indicating that they did so. 
 
In expanding on what work they do outside their own pharmacy, many worked in other 
pharmacies as a locum or providing cover for another pharmacy within the group or chain, 
both regularly and ad hoc. Many were involved in the CPD/CE aspect, developing, reviewing, 
and/or delivering modules for the ICCPE, IPU, and others. Others were involved in the PSI 
and/or IPU activities, and some mentioned contributing articles to pharmacy publications such 
as the IPU magazine. 
 
  




The following graph shows the gender breakdown of the respondents: while a little over 2% 
did not answer the question, 51.4% were female and 46.4% were male. 
 
Figure 5: Gender 
 
 
2.2.7 Age Group 
 
Participants were asked to indicate their age group. The following graph illustrates the 
responses. The biggest category represented was those under 35 (almost 39%), with the 
second-biggest group being those between 35 and 44 (35%). 
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2.2.8 Number of Years Registered 
 
We asked the respondents to indicate how many years they had been registered as a 
pharmacist. The average (mean) was more than 15 years, with the most common response 
being 10 years. The minimum was 2 years and the longest time that a survey respondent had 
been registered was 53 years. The following histogram shows the distribution: 
 




2.2.9 Institution where Pharmacy Degree Undertaken 
 
When asked which institution awarded the respondents their primary pharmacy degree; of 
those who responded, 37% undertook their degree at TCD, 43% at UCD, 5% at the former 
College of Pharmacy in Shrewsbury Road, and 0.2% (1 respondent) at UCC. The others 
received their degrees from institutions outside Ireland, with 5.5% stating that their degree 
was from a Northern Irish school of pharmacy, 38% from other UK schools of pharmacy, a 
little over 5% from other EU institutions, and 2% from outside the EU. 
 
2.2.10 Areas of Pharmacy Practice 
 
Respondents were asked to tick all of the relevant areas of pharmacy in which they had 
practised. Unsurprisingly, all (except one), 99.8%, included community pharmacy, 23.4% 
indicated they had undertaken hospital pharmacy, 5.8% had worked in industry, and another 
4.5% in research. (Note that the percentages do not add up to 100% because respondents 
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Figure 8: Pharmacy Practice Areas 
 
 
2.2.11 Representative Nature of Survey Responses 
 
The PSI compared the profile of the survey respondents with the profile according to the PSI‟s 
register (in terms of age, geographic distribution, etc) and they are closely matched.  This 
gives confidence that the respondents comprise a representative sample of community 
pharmacies and community pharmacists and consequently that their responses can be taken 
to represent the views of the full population of community pharmacy. 
 
  




3.1 PHARMACY ACTIVITY 
 
In order to gauge typical core pharmacy activity, we asked pharmacists to indicate how many 
prescriptions they dispensed in a typical month. More than a quarter, 26.5%, had prescription 
dispensing numbers in excess of 5,000 per month, as shown in the graph below: 
 
Figure 9: Prescription Items Dispensed in Typical Month 
 
 
International Comparison Notes: 
 
In Ireland, Germany and Switzerland there was a significant positive relationship between 
pharmacists‟ Behavioural Pharmaceutical Care Scale (BPCS) scores and the total number of 
dispensed items per day (Hughes et al, 2010). 
 
Other work in US non-urban locations in 2005, however, found an association between 
providing drug therapy services and lower workload per pharmacist (Gadkari 2009).  
 
 
We then asked pharmacists to indicate the breakdown of their prescription dispensing activity 
by giving the figures for a typical month for each of a number of categories, including private, 
DPS, GMS, LTI, high-tech, and so on. The following graph shows the mean number of 
prescriptions within each category. We can see from the chart that GMS prescriptions 
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Figure 10: Average Prescriptions Dispensed in Certain Categories 
 
The responses relating to the “Other” prescription category included veterinary prescriptions, 
those issued under schemes like the hardship scheme or for EU nationals, psychiatric 
prescriptions, hospital emergency prescriptions, and dental prescriptions. 
 
3.2 RESIDENTIAL CARE SETTINGS 
 
We asked respondents to tell us whether they provided services to residential care settings. 
Of those who responded to the question, 32.7% did provide services to settings of this kind. 
 
International Comparison Note: 
 
The comparable rate in England for the provision of services to the broad, self-defined 
category of residential care settings was 18.4% in 2006 (Bradley et al 2006). 
 
Participants were then asked to expand on the types of care settings and the types of 
services provided to such settings. Nursing homes represented the most common type of 
care setting served, with other residential care homes (such as residential units for people 
with intellectual disability) the next biggest category. No respondent indicated that they 
provided services to prisons, with only a handful offering services to homeless hostels and 
other care settings (3 and 4 respondents respectively). The average number of nursing 
homes served by those who provide pharmacy services to such settings was 2.4; this may be 
skewed by the maximum but by no means typical figure of 49. 
 
Similarly, when asked to indicate the numbers of patients served by the pharmacy within 
residential care settings, the highest numbers relate to nursing home patients. The average 
number of nursing home patients to whom services are offered is 63; most commonly 
pharmacies serve 20 patients per nursing home. The mean average is again influenced by 
the high maximum figure of 1,245. The average number of patients in other residential care 
settings is 19; the two pharmacies who gave details about their services to homeless hostels 
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indicated respective patient figures of 41 and 50; and “other care settings” averaged 18 
patients. 
 
In terms of the services provided, respondents indicated that they dispensed prescriptions to 
patients in residential care settings as the most common service, followed by the provision of 
advice, then monitored dosage systems, and medication reviews. 
 
3.3 PROVISION OF ENHANCED PHARMACY SERVICES 
 
A key element of the Baseline Study was to examine the current service offering within 
pharmacies across the country, with a particular emphasis on the extent of the provision of 
enhanced pharmacy services. We defined enhanced pharmacy services within the 
questionnaire as follows: “An enhanced pharmacy service refers to a service implemented in 
pharmacies that is additional to or not routinely provided with prescribed or non-prescribed 
medicines. The service is often characterised by facilities and/or devices dedicated to the 
service and staff who are competent or formally trained and for which a private fee may or 
may not be charged.” 
 
The following table outlines the numbers of respondents and the percentage they represent of 
those who responded to the question for each of a range of enhanced pharmacy services. 
 
Table 2: Enhanced Pharmacy Services 
 Provide currently If not currently 
provided, would like to 
provide in future 
If not currently 
provided, would not 
like to provide in 
future 
No. % No. % No. % 
Disposal of Unwanted Medicines 426 94.5% 22 4.9% 3 0.7% 
Monitored Dosage Systems 399 90.7% 25 5.7% 16 3.6% 
Home Delivery Services 224 54.9% 85 20.8% 99 24.3% 
Supervised Methadone Service 140 36.1%
a
 74 19.1% 174 44.8% 
Needle Exchange 10 2.7%
b
 128 35.1% 227 62.2% 
Fertility Treatment Dispensing 
Services 
240 60.5% 127 32.0% 30 7.6% 
Veterinary Pharmacy Services 104 26.5% 126 32.1% 162 41.3% 




 222 54.8% 63 15.6% 
Palliative Care 201 48.6% 193 46.6% 20 4.8% 
Structured Medicine Use Reviews 59 14.3%
d
 331 80.0% 24 5.8% 




 337 78.4% 17 4.0% 
Nutrition / Exercise 96 22.9% 293 69.9% 30 7.2% 
Obesity / Weight Management 168 39.1%
f
 238 55.3% 24 5.6% 
Sexual Health 21 5.2% 329 81.0% 56 13.8% 
Blood Pressure Screening 208 47.5% 201 45.9% 29 6.6% 
Lipid/Cholesterol Screening 47 11.1% 324 76.4% 53 12.5% 
Diabetes Screening 72 17.0% 307 72.6% 44 10.4% 
Weight/Height/BMI Assessment 246 56.8% 163 37.6% 24 5.5% 
Lung Capacity Screening 14 3.3% 343 81.9% 62 14.8% 
Osteoporosis Screening 8 1.9%
g
 327 79.0% 79 19.1% 
Pregnancy Testing 12 2.9% 285 68.8% 117 28.3% 
PSA (Prostate-Specific Antigen) 
Screening 
0 0.0% 326 79.3% 85 20.7% 
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International Comparison Notes: 
 
a 
The comparable figure for methadone in: England is 31.1% (Bradley et al. 2006). 
b 
Needle exchange service provision in England is 15.7% (Bradley et al. 2006). 
c 
The residential care homes services figure for England is 18.4% (Bradley et al. 2006). 
d 
The figure for medicines use reviews (MUR) in England, which may differ from the service in 
Ireland, is 1.4% (Bradley et al. 2006). 
e 
Figures for smoking cessation services are 35.8% for England and 19% for Australia 
(Bradley et al. 2006 and Berbatis et al. 2007 resp.). While it is our opinion that smoking offers 
the best comparison, the studies were done at different times so this limits comparison 
somewhat. 
f 
The comparable figure for obesity/weight management services in Australia is 8.7% (Berbatis 
et al. 2007). 
g 
The osteoporosis screening figure for Australia is 6.6% (Berbatis et al. 2007). 
 
It is interesting to note that the first two services, disposal of unwanted medicines and 
monitored dosage systems, at 95% and 91% respectively, are so widely provided as to make 
them effectively core services in Irish pharmacies. Monitored dosage systems were noted in 
the qualitative interviews as having increased in prominence in recent years (see Section 3.8 
below). 
 
Participants were also asked to indicate any services not mentioned that they currently 
provide in their pharmacies, and to suggest additional services they would like to provide. 
Some of the services being provided currently include inhaler technique for asthmatic 
patients, stoma care, measurement for compression hosiery, and food allergy testing. 
Services that pharmacists would like to see in place include vaccinations, INR blood testing 
for Warfarin patients, and pharmacist prescribing. 
 




Arising from the qualitative interviews, we identified three of the diagnostic services above, 
blood pressure screening, cholesterol screening, and diabetes screening as representative of 
the types of services many perceive as potential enhanced pharmacy services. We have 
undertaken further analysis on the potential influences on the provision or appetite to provide 
such services in terms of variables such as the age of the pharmacist, the location (city 
versus small town, etc), and the mix of prescription types (i.e. the percentage of GMS 
patients). The analysis has been undertaken on variables created by combining the 
responses to the question regarding whether pharmacists currently provide or would like to 
provide one or more of the three diagnostic services concerned, and was conducted by Dr 
John Newell, a biostatistician in NUI Galway. A summary of his findings follows; the full 




Data were provided from a sample of 457 pharmacies in Ireland where interest was in 
identifying those explanatory variables (of the eight provided) that were useful predictors of 
whether a pharmacy already provides enhanced services or are willing to do so. 
 
Initially, an analysis of the usefulness of each explanatory variable separately was performed 
(using the Chi square test or two sample t-test as appropriate). Pharmacy Location, 
Pharmacy Type, and % GMS Prescription Percentage were identified as potentially useful 
predictors of provision of enhanced services. Pharmacy Location, Pharmacy Type, and 
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Pharmacist‟s Age were identified as useful predictors of willingness to provide enhanced 
services. 
 
Further analysis was undertaken using Logistic Regression and Classification Tree 
methodologies to explore the relationships further. In the former approach, the odds of a 
pharmacy providing or being willing to provide enhanced services is modelled as a function of 
the explanatory variables where the main aim is to identify the minimally useful subset of 
explanatory variables. Initially, a full model (i.e. including all explanatory variables and their 
interactions) were fitted. Variable selection procedures were then used to identify which 
variables can be dropped from the model as deemed unnecessary. 
 
The second approach considered involved fitting Classification Trees to uncover structure in 
the sample provided that may be reflective of real effects in the population of pharmacies of 
interest. Tree-based procedures should be interpreted with care, however, as they are data 
driven approaches and all results uncovered should be considered as exploratory. Trees were 
fit and pruned using recursive partitioning, chi square automatic interaction detection and 
conditional trees approaches 
 
3.4.3 Current Provision of Sample Enhanced Services – Predictors 
 
When considering factors that are likely to predict whether a pharmacy, in the population of 
interest, provides enhanced services or not, logistic regression identified that Pharmacy Type 
is an important predictor. Pharmacies with 6 or more outlets were twice as likely to provide 
enhanced services compared to single-outlet pharmacies, with little difference between 
pharmacies with 2-5 outlets and single pharmacies. 
 
The Location of the pharmacy is an important predictor also: pharmacies in mid-sized 
towns were identified as being half as likely to provide enhanced services compared to 
pharmacies in cities. 
 
There was also a suggestion, based on the use of Classification Trees, that percentage of 
GMS Prescriptions may also be a useful predictor, where a pharmacy with less than 26% 
of GMS Prescriptions is more likely to provide enhanced services. 
 
3.4.4 Willingness to Provide Sample Enhanced Services – Predictors 
 
Logistic Regression identified that younger pharmacists (44 and younger) are more likely 
to be willing to provide enhanced services compared to older pharmacists, as are 
pharmacies that are part of 2-5 outlets. Classification Trees suggested that information 
relating to the percentage GMS prescriptions a pharmacy has is important also, with 
willingness to provide enhanced services increasing with increasing percentage but only in 
the large and small pharmacies. 
 
3.5 INTERNATIONAL FINDINGS RELATING TO THE DEVELOPMENT OF PHARMACY SERVICES 
 
Through the results sections of the report (commencing at Section 3.8.3), international studies 
in related fields will be presented as a series of „international vignettes‟. It is recognised that 
direct comparison is limited between initiatives in countries that differ in terms of pharmacy 
and health services infrastructure, and payment systems. These vignettes will illustrate 
relevant and complementary issues that have been explored in other pharmacy contexts. 
 
3.6 TIME SPENT ON PHARMACY ACTIVITIES 
 
We asked respondents to identify how much time they spend in a typical week on a range of 
pharmacy activities. The activity taking the most time in a typical week was dispensing 
prescription medicines, identified by 81.2% of respondents as taking most of the time on most 
days. Other key activities in terms of the time typically spent being „most or some of the time 
on most days‟ were counselling prescription patients (94%); counselling non-prescription 
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patients (89%), and giving advice about minor illness (90%). Significant time is also spent on 
stock management and administration duties. 
 
The activities with less impact on time for pharmacies included attending health-related 
meetings; CPD activities; audit and practice research; and adverse drug reaction 
reporting/follow-up. 
 
“Other” activities taking up time were stated as paperwork, house calls/home delivery, visiting 
local GPs, communicating with and advising nursing homes, and dealing with ad hoc queries 
from patients when out and about. 
 
The following table illustrates the responses to this question, showing the number and 
percentage of responses in each category. 
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Table 3: Time Spent on Pharmacy Activities 
Activity 
Most of the time on most 
days 
Some of the time on 
most days 
Some of the time on 
some days 
Little time on few days Never 
 No. % No. % No. % No. % No. % 
Dispensing Prescriptions 366 81.2% 82 18.2% 3 .7% 0 .0% 0 .0% 
Counselling Prescription Patients 152 33.6% 273 60.3% 21 4.6% 6 1.3% 1 .2% 
Counselling Non-Prescription 
Patients 
94 20.8% 307 68.1% 44 9.8% 5 1.1% 1 .2% 
Giving Advice about Minor Illness 89 19.8% 315 70.0% 37 8.2% 9 2.0% 0 .0% 
Giving Advice about Long-Term 
Conditions 
42 9.4% 196 43.9% 157 35.2% 51 11.4% 0 .0% 
Giving Advice about Healthy 
Lifestyles 
34 7.6% 129 29.0% 176 39.6% 98 22.0% 8 1.8% 
Other Pharmacy Services in 
Pharmacy 
7 1.6% 62 14.3% 116 26.8% 181 41.8% 67 15.5% 
Other Pharmacy Services Outside 
Pharmacy 
6 1.5% 24 6.0% 45 11.3% 104 26.1% 220 55.1% 
Communicating with Other 
Healthcare Professionals 
23 5.2% 154 34.7% 160 36.0% 97 21.8% 10 2.3% 
Attending Health-Related Meetings 1 .3% 7 2.0% 72 21.1% 159 46.5% 103 30.1% 
CPD Activities 1 .3% 23 7.7% 124 41.5% 142 47.5% 9 3.0% 
Audit and Practice Research 3 .8% 25 6.6% 129 34.3% 188 50.0% 31 8.2% 
Adverse Drug Reaction 
Reporting/Follow-up 
11 2.6% 31 7.2% 80 18.6% 259 60.1% 50 11.6% 
Patient Eligibility for Support 18 4.1% 85 19.3% 160 36.3% 154 34.9% 24 5.4% 
Stock Management 96 21.5% 248 55.6% 79 17.7% 23 5.2% 0 .0% 
Other Administration/ Management 
Duties 
90 21.4% 232 55.2% 73 17.4% 21 5.0% 4 1.0% 
Staff Training 17 3.9% 80 18.4% 209 48.0% 118 27.1% 11 2.5% 
Merchandising 13 3.1% 50 11.7% 134 31.5% 155 36.4% 74 17.4% 
Breaks 53 12.4% 107 25.1% 60 14.1% 118 27.6% 89 20.8% 
Out-of-Hours Availability 34 8.6% 26 6.5% 56 14.1% 125 31.5% 156 39.3% 
Other 4 12.5% 2 6.3% 5 15.6% 3 9.4% 18 56.3% 
 PSI Baseline Study Final Report 
20 
 
Respondents were also asked to indicate which activities took up their time outside normal 
working hours. The main category identified in this regard was CPD activities, along with 
attending health-related meetings and audit and practice research. The graph below 
illustrates these responses: 
 
Figure 11: Activities Undertaken Outside Working Hours 
 
 
3.7 WRITTEN/NON-VERBAL INFORMATION 
 
We asked participants to tell us what written or non-verbal information the pharmacy offered 
to patients; the vast majority of the respondents indicated that leaflets and referral to websites 
and/or patient support groups constituted the bulk of the non-verbal information offered. 
 
3.8 QUALITATIVE INTERVIEWS – SERVICES 
 
3.8.1 Change – Past 
 
We started each interview with questions to the pharmacist as to their perception of how 
pharmacy or their individual practice had changed in the preceding years. There was mixed 
response to this. Many suggested that in some ways little had changed, particularly 
when it came to core dispensing services. For some, this was evidence that Ireland lags 
behind other countries when it comes to the development of enhanced services. 
“The basic dispensing and looking after the customer hasn’t changed from my experience as a 
pharmacist. What I am doing now I always did with the patient.” 
“I feel that it’s sort of been stuck in a situation that things have not changed in the last number of years.” 
 
Many pharmacists mentioned an overall increase in the workload in the pharmacy, arising 
from an increase in administrative duties (see below) in respect of the requirements of the 
Pharmacy Act and the reimbursement from the HSE and from the increase in the range and 
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complexity of medicines now being prescribed. The need to keep up with the 
developments in medicines takes more time now. 
“The developments in medicine – as the number and complexity in medicine grows, so I suppose the 
complex nature of the job increases.” 
 
Several commented on the increasing level of paperwork, both in terms of the provisions 
and requirements of the Pharmacy Act, and the complex reimbursement processes for the 
various schemes operated by the State. For many pharmacists, this aspect of the job is taking 
increasing time and resources, which they would prefer to spend counselling patients or 
developing pharmacy services. 
 
Linked to the increasingly complex range of medicines, pharmacists also noted the marked 
increase in the demand for monitored dosage systems or blister packing, which they 
provide to patients who need such aids to compliance – mostly elderly or chronically ill 
patients. Several commented that this had represented a significant increase in time and 
resources in recent years. 
 
Interviewees mentioned that they are doing more patient counselling than previously, 
again increasing the time spent on dispensing prescriptions to patients. Coupled with the new 
codeine regulations requiring pharmacists to counsel patients requesting codeine-based 
products, this results in considerably more time spent at the counter with patients. 
 
The overall pressure on pharmacists in terms of workload is perceived to be greater now than 
in previous years. This is exacerbated by the worries many have in relation to the survival 
of the pharmacy as a business in the current economic climate. Reductions in fee 
income and increases in workload mean that many state that they are concerned about the 
viability of the business aspect of the pharmacy. 
 
3.8.2 Change – Future 
 
We asked pharmacists to describe the changes they would like to see in the future. While 
much of this response overlapped with, and will be covered in the sections regarding the later 
questions in respect of services the pharmacist themselves would like to provide, and those 
they believe should be considered by the pharmacy profession overall, there were some 
aspects of this question that related to a more general image of what pharmacy should look 
like in Ireland in future. Many responses were, obviously, the converse of the preceding 
question: if people felt that the burden of paperwork and regulatory requirements was 
excessive, then their view of what should change in the future was for these to be reduced; 
similarly if they feel that pharmacy service is underdeveloped in Ireland, they would like to see 
progress in this area in the coming years. 
 
3.8.3 Lack of Recognition for Pharmacy 
 
One key issue that pervades almost every interview is the feeling among pharmacists that 
their role, skills, knowledge, and practice are underestimated, undervalued, and under-
recognised in the current healthcare delivery structure. Many are concerned at the 
exclusion of pharmacies from the formation of primary healthcare teams. Pharmacists are 
angry that their work is measured solely in terms of numbers and types of prescriptions 
dispensed rather than the quality of their patient interactions or counselling. This relates to 
several stakeholders: pharmacists feel that the remuneration model is flawed because it fails 
to recognise areas that pharmacists could and should be contributing to delivering patient 
care and saving the health system money; many also feel that the PSI looks only at technical 
aspects of pharmacy practice and does not take into account the patient-centred nature of 
many pharmacies‟ activities. Patients, too, can take for granted the easy access to free health 
and medicines advice. 
 
There is concern among many of the interviewees that there appears to be no overall plan 
for how pharmacy should be developed and where it should fit within the delivery of 
healthcare services to patients. Many commented that the HSE did not have a clear vision 
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of where pharmacy should sit within the structure of services, and that without such a vision, 
the future development of the profession would not be coherent or meaningful. As further 
explored below, pharmacists feel that there are many ways in which they could contribute to 
improved patient health, while saving the health system money and resources at the same 
time, but that this potential was being overlooked and undervalued. 
“There is a blockage of mind set within the HSE … Traditionally we were just seen as dispensers; in 
their mindset we will always be dispensers.” 
“I suppose I’d like to see the things that we do that aren’t recognised being recognised more, in the 
sense that a lot of what we do isn’t recognised by, say, the people who are providing them, say even 
things like that. We’re paid sometimes for ridiculous things and then we’re not paid for the things we 
spend an awful lot of time on, so I would like to see those kinds of things being recognised more.” 




Changes in the community pharmacy contractual framework (CPCF) in England and 
Wales since 2005 – Enhanced Services (Blenkinsopp et al. 2007) 
 
The evaluation of the new community pharmacy contract explored the growth in 
commissioning and provision of community pharmacy services. The new CPCF provided a 
mechanism of paying pharmacists for services other than dispensing. Beyond „essential 
services‟, there were tiers of enhanced and advanced services. The main „advanced service‟, 
funded centrally with a national specification, was medicines use review (MUR). There was 
also a suite of enhanced services that could be commissioned, specified and remunerated 
locally according to the needs of the population – and the aspirations of pharmacists. The 
evaluation showed that commissioning of cognitive pharmacy services such as repeat 
dispensing, medication reviews (different from MUR in scope) and management programmes 
for specific long-term conditions increased sharply after implementation of CPCF in 2005. 
Other services such as care homes advice and minor ailments showed more modest 
increases. The evaluation also found that, post-CPCF, only 13% of pharmacies were not 
providing any enhanced services, and that 43% were providing 3 or more enhanced services. 
 
3.8.4 Current and Future Service Provision 
 
Most pharmacists felt that the work that they are currently doing was of a high standard. The 
majority are delivering core dispensing and OTC medicine services, along with the retail front-
of-shop activities common to most community pharmacies. Some were doing certain 
enhanced services like smoking cessation, weight management, blood pressure monitoring, 
etc. A few were doing more advanced blood testing screening and diagnostic services. 
 
The appetite for providing enhanced pharmacy services in future was mixed. Overall, the 
majority of those we spoke to were keen to provide enhanced services such as health 
promotion programmes (e.g. weight loss or smoking cessation), and screening, diagnostic 
and monitoring services like blood pressure measurement, blood sugar testing for diabetes, 
cholesterol levels, and Warfarin levels. However, there are many who believe that the key 
skills of pharmacists remain with medicines expertise and core dispensing of prescription and 
OTC medication. While the former see the expansion into screening, monitoring, and 
diagnostic testing as a natural extension of the pharmacy practice, the latter group were 
concerned that such innovations might dilute or devalue the core of pharmacy as a 
profession, and that promoting such services did a disservice to the existing practice of 
pharmacy. 
 
“I would do all of those services, blood pressure testing, cholesterol testing, diabetes, blood sugars, all 
that sort of thing. I’d be very interested in it.” 
“I would expect pharmacy services to develop into the future with the new consultation rooms to allow 
us to, we do already measure blood pressure and BMI, we could do things like cholesterol/glucose 
testing, INRs for people who are on Warfarin, you know; vaccinations and so on.” 
“Any expansion is belittling what is done by pharmacists. The core of pharmacy should be brought up to 
a much higher level before any type of expansion can even be considered, let alone started.” 
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“I would prefer to be an expert in that area than to have all the vaccinations and blood pressure taking 
and the blood testing. My wish would be to develop my core profession.” 
 
Almost every pharmacist we interviewed, however, was agreed that pharmacy in Ireland 
could and should expand into two key areas: 
 medicines use reviews (MURs); 
 minor ailment schemes: 
o limited pharmacy prescribing; 
o change of status for several medicines from prescription-only to pharmacist-
supervised sale. 
 
Medicines Use Reviews (MURs) 
 
The development of formalised medicines use reviews was mooted by nearly every 
interviewee. These MURs would, the pharmacists believed, benefit patients, doctors, 
pharmacists, and the State. By formally reviewing, in collaboration with the GP and/or hospital 
prescribers, the full range of medicines being prescribed for an individual patient, the 
pharmacist could, consultees believe, identify overlaps or contra-indications for some 
medicines, potentially changing, reducing, or reconfiguring the medicines to produce the 
same or better outcomes for the patient, possibly with fewer side-effects. The obvious benefit 
to patients aside, MURs would also enable physicians to manage the conditions more 
effectively, potentially save the State significant amounts of expenditure on medicines, reduce 
interactions and increase effectiveness – thereby reducing, for example, presentations to 
hospital or lengths of stay in hospital, and utilise the medicines knowledge and expertise of 
the pharmacists themselves: as discussed above, something many feel is under-appreciated 
and under-used in everyday dispensing practice. 
 
It should be noted that the Houses of the Oireachtas Joint Committee on Health and 
Children‟s Report on Primary Medical Care in the Community
3
 (February 2010) recommended 
the introduction of MURs by pharmacies, and the same committee‟s April 2007 report on 
Adverse Side-Effects of Pharmaceuticals
4
 also endorsed pharmacist MURs. 
 
In a related vein, pharmacists are keen to address the issue of compliance among patients, 
that is, patients not taking their prescribed medicines correctly or even at all. Pharmacists can 
identify compliance issues with their patients, especially by dint of the simple observation of 
how often prescriptions are being refilled – if this is less often than the doctor indicated, then 
the patient may be taking less medication less often than prescribed, with consequently less 
effective outcomes, further prescriptions (possibly of increased or stronger medication) to try 
to control the condition, and so on. As with MURs, pharmacists believe that addressing 
compliance problems helps the patient, the doctor, and the State. Pharmacists commented 
that it is frequently in the pharmacy that a patient mentions problems with medication, such as 
side-effects, that may be discouraging the correct use. Those interviewed believed that this 
presents an opportunity to discuss the importance of compliance with the patient, potentially 
leading into a full MUR to assess whether some problems could be resolved by tweaking the 
medication or mix of medications. 
 
International Vignette: 
Medication Therapy Management – Profession-wide consensus in the US (Hansen et al, 
2006) 
 
Pharmacists in the US have developed a definition of „medication therapy management‟ that 
comprises 9 components. In this survey of pharmacists in North Carolina in 2005, the 
percentage of pharmacists delivering some/all of these components was as shown in the table 
below: 
                                                 
3
  Houses of the Oireachtas Joint Committee on Health and Children, Report on Primary Medical Care in the Community, 
February 2010 
4
   Houses of the Oireachtas Joint Committee on Health and Children, Report on Adverse Side Effects of Pharmaceuticals, 
April 2007 
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Table 4: Medication Therapy Management Delivery in N Carolina 
Component % of pharmacies 
providing service 
(n=262) 
Number of patients 




Providing verbal education and training designed to 
enhance patient understanding and appropriate use 
of his/her medication 
39 14 (5-49) 
Co-ordinating and integrating MTM services within the 
broader health care management services being 
provided to the patient 
37 N/A 
Performing a comprehensive medication review to 
identify, resolve and prevent medication-related 
problems, including adverse drug events 
31 5 (1-35) 
Providing information, support and resources 
designed to enhance patient adherence with his/her 
therapeutic regimen 
26 10 (1-42) 
Selecting, initiating, modifying, or administering 
medication therapy 
19 6 (1-21) 
Performing or obtaining necessary assessments of 
the patient‟s health status 
15 3 (1-14) 
Formulating a medication treatment plan 11 2 (1-7) 
Monitoring and evaluating the patient‟s response to 
therapy, including safety and effectiveness 
11 35 (5-70) 
Documenting the care delivered and communicating 
essential information to the patient‟s other primary 
care providers 
10 3 (1-25) 
Providing comprehensive services encompassing 
aspects of all the above 
31 25 (5-140) 
 
 
Minor Ailment Schemes: Pharmacist Prescribing/Change of Status of Prescription 
Medicines 
 
Most of those interviewed believed that the current structure and legal framework regarding 
prescription medicines was too restrictive, and that pharmacist prescribing should be 
developed in the coming years as part of a minor ailment treatment scheme. In the meantime, 
many suggested that a simpler route for some medicines would be to downgrade them from 
prescription-only to be sold under the supervision of a pharmacist. Several suggested looking 
at medicines such as those available in UK pharmacies, e.g. Diflucan, or the morning-after 
pill. 
 
Interviewees suggested that such schemes could be of benefit to patients, in affording them 
cheaper and more convenient access to treatment for minor ailments; could address the 
strain on GP services becoming evident in recent years; and could again save the HSE 
expenditure on A&E visits and treatment of complications arising from minor untreated 
ailments. This type of scheme would also, they felt, address the perceived under-utilisation of 
pharmacist skills and qualifications, and provide more professional satisfaction for 
pharmacists. 
 
The Report on Primary Medical Care in the Community (mentioned above) from the 
Oireachtas Joint Committee on Health and Children was also favourable to pharmacist 
involvement in Minor Illness Schemes. 
  




Pharmacist Prescribing (Canada) (Management Committee CPhA, 2008) 
 
In Alberta, Canada, since 1st April 2007, pharmacist prescribing has been legally facilitated 
and encompasses: 
 Adapting prescriptions (altering dosage, formulation or regimen) 
 Therapeutic substitution 
 Extending a prescription to ensure continuity of care 
 Emergency prescribing 
 Additional prescribing authorisation (initial access prescribing and managing ongoing drug 
therapy). 
Pharmacists must be on a special provincial register and complete an orientation programme. 
The application for authorisation includes documentation of the pharmacist‟s education, 
training, practice, experience and collaborative relationships. 
 
3.8.5 Payment for Enhanced Pharmacy Services 
 
We posed the question to the interviewees as to who should be paying for such expanded 
services as screening or minor ailment treatment. The majority suggested that the current 
mixed model as applying to GP visits and prescriptions should apply: that is, the HSE should 
fund such services if supplied to GMS patients or those on specific schemes (e.g. for 
monitoring of long-term conditions) and that private patients should pay for services 
themselves, and/or that private health insurers should cover such costs on behalf of their 
customers. 
 
This was not a universal viewpoint, however; many felt that the State should cover the cost for 
all patients, depending on the service, given that the benefits such as early diagnosis for 
many conditions actually achieve long-term savings in expenditure for the health services 
down the line. Others were critical of the free model, indicating that patients should pay even 
a nominal amount towards all primary healthcare services, because of the perceived 




Pharmacists were asked what their main motivations were for providing or wishing to provide 
improved or enhanced services. Most stated that their primary motivation was to provide an 
improved service to patients by increasing access to certain services, by improving 
outcomes and quality of life by means of MURs, and reducing cost to patients. They also 
mentioned saving the State money through the introduction of MURs and minor 
ailment/pharmacist prescribing schemes. Interviewees also suggested that providing new 
services could act as a marketing tool to attract new patients to the pharmacy, and that if 
there was a remuneration scheme in place or if patients were to be charged for the services, 
they could represent new revenue streams for the business. 
 
3.8.7 Barriers to the Development of Expanded Pharmacy Services 
 
We asked pharmacists what stood in the way of expanding pharmacy services into new 
areas. Some, as mentioned above, didn‟t believe that pharmacy should significantly move 
away from its current dispensing core function, other than perhaps into MURs and the ability 
to dispense more medicines than at present as discussed previously. 
 
Where pharmacists were keen to see changes, especially in the screening and diagnostic 
fields, they identified three key barriers: 
 Staff: not enough qualified staff to take on new services; 
 Time: too little time to devote to setting up or running such services; 
 Money: they did not have the financial resources to develop new pharmacy services. 
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In effect, one can distil these three issues into one: money. If pharmacies had a different 
income model, the interviewees suggested, one that generated income for all the services 
provided, then they could pay for more qualified staff, which in turn would free up the time of 
the supervising pharmacist and others to develop and run these enhanced services. 
 
There were, of course, other barriers identified. Many of those we interviewed mentioned 
opposition by local GPs and other healthcare providers to the extension of diagnostic 
or treatment services to pharmacy. Some indicated that this opposition was motivated by 
financial concerns: if patients can access tests, monitoring, minor ailment treatments, and so 
on in pharmacies, this will impact on fee income for GPs. Others mentioned the lack of 
confidence in, or understanding of, the qualifications of pharmacists by other medical 
professionals, and a consequent reluctance to “hand over” services previously the domain 
solely of doctors to the pharmacy profession. 
 
“I approached the local doctor and he wasn’t at all keen on it and I didn’t want to tread on his toes.” 
“Some doctors aren’t too happy with pharmacists providing services that were traditionally theirs.” 
“There would be a danger that other professions would see it as treading on their toes. And given the 
fact that in the current environment doctors can influence patient’s choice of pharmacy, that can tend to 
frighten patients or pharmacies off expending their services for fear that they would antagonise the local 
doctor who would take their existing bread and butter away from them.” 
 
Some were concerned about the clinical requirements for conducting, for example, blood 
tests. Training in aseptic procedures, appropriate sterile environments, sharps handling and 
disposal, the necessity to install sinks in consultation rooms, and similar concerns were raised 
in this regard. 
 
The availability of specific, validated training in such procedures was also flagged as 
something that might stand in the way of expanding services. More on this issue is discussed 
in Section 7: CPD and CE. 
 
Another barrier to the future development of services was the conflict perceived at times 
between the business and clinical aspects of community pharmacy, i.e. the difficulties in 
reconciling the delivery of services to patients with the commercial demands of maintaining a 
profitable business. Decisions that might improve patient care sometimes have to take a back 
seat to the economic necessities. 
“Sales become the imperative when pharmacists are looking at the bottom line, and that’s something 
that causes huge conflict with one's ability to deliver quality pharmaceutical care.” 
“I just feel I am running around dealing more with the business than I am with the patient.” 
“The pressures of managing a business: all these things take time…if you are the shop owner, you 
know, you’re running the business and it’s very hard to have staffing levels to do all those kind of thing 
because you don’t see your pound’s worth coming in straight away so it’s very hard to value the benefit 
to your business at the moment.” 
 
International Vignette: 
Barriers and facilitators to providing enhanced pharmacy services in Australia 
(Berbatis et al. 2007) 
 
The major barriers identified by Australian pharmacists in 2002 were lack of time and 
shortage of pharmacists. The major facilitators were dedicated study time, accreditation, 




We asked pharmacists to consider the question in the other way: what would enable them to 
develop new or improved pharmacy services? Again, the core issues came back to money, 
time, and workforce. If income was greater and more stable, if pharmacists had more time, 
and if they could employ more qualified staff, they could develop new services. 
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Other issues that were mentioned included the actual demand for such services among 
their catchment of patients. Those who have a high proportion of GMS patients were sceptical 
that they would come to a pharmacy for a service that they already access free of charge at 
their GP. This would be especially relevant in the event that the services being provided in the 
pharmacy were being charged for, albeit at a rate lower than a private patient would pay a 
GP. Pharmacists did feel, however, that if there were sufficient demand for enhanced services 
among their patient profile, they would consider developing them in response. 
 
Pharmacists noted that the current legislation and regulations regarding the licensing of 
medicines would need to change to facilitate pharmacist prescribing and/or the change in 
status of medicines from prescription-only to pharmacist-supervised. 
 
In order to achieve real benefits from the development of MURs, pharmacists believe that a 
formal structure would need to be implemented in conjunction with GPs and other 
healthcare providers to ensure that the recommendations arising from a medicines use 
review are implemented and the outcomes measured so that the benefits can be assessed. 




Barriers and Facilitators (England/Wales) (Blenkinsopp et al. 2007) 
 
The three most often cited barriers to delivering the new community pharmacy contract were 
lack of time, lack of funding and lack of skilled support staff. The three most often cited 
facilitators were general support, training sessions and „very little‟. In focus groups within the 
evaluation, the pharmacists spoke of a lack of ownership of the contract: they felt that it had 
been decided by the negotiators and large multiples, rather than individual pharmacists. This 
lack of ownership resulted in low motivation. There was also a feeling that the initial 
information about the contract had been too simplistic, and that the detail had been emerging 
over time, which was unsettling and increasingly onerous. The evaluation summary of the 
facilitators and barriers is reflected in the table. 
 
Table 5: Facilitators and Barriers to New Community Pharmacy Contract in UK 
Facilitators Barriers 
Increased patient contact as a motivator for 
many pharmacists 
Feelings of lack of ownership of CPCF among 
employees and, among owners, of details of the 
contract which emerged after contractors had voted 
for it 
PCO level resources to engage and support 
local pharmacies to implement change 
Increased workload of pharmacists 
Pre-existing positive relationship between PCO 
and LPC and mechanism for discussing local 
development 
Insufficient people resource capacity (pharmacy 
support staff) 
Motivation and drive of individual pharmacists Opportunity cost of increased record keeping 
Support and resources for implementation from 
employing companies 
Little or no existing relationship between some 
pharmacies and GP practices 
Installing consultation facilities in the pharmacy 
GP perception that changes as a result of CPCF 
increased rather than decreased their workload 
Pre-existing positive relationship between the 
pharmacy and the local practice/s 
Lack of public awareness of the new contract 
 
 
3.8.9 Role for the PSI and/or Other Organisations 
 
Interviewees were asked to consider whether the PSI and/or other organisations could play a 
role in the development of new or improved pharmacy services. (Further comment appears at 
Section 9.3 below.) It is worth noting some of the suggestions about what could be done at a 
wider level to support pharmacists in developing pharmacy services, including the following: 
 PSI Baseline Study Final Report 
28 
 The PSI’s role in enforcing and maintaining high standards for pharmacy should 
contribute to developing new services both by ensuring that pharmacies are delivering 
services in a safe and professional manner and by improving the reputation of pharmacy 
as a professional service; 
 The PSI should promote pharmacy to the HSE and others as a profession and push for 
more recognition and integration of pharmacy in terms of the wider healthcare agenda; 
 HSE should develop a clear vision for how pharmacy can contribute to the delivery of 
healthcare services to the population and how it can be integrated into the existing and 




Organisational change in the implementation of cognitive pharmacy services 
(Australia) (Roberts et al, 2006) 
 
This conceptual review of the literature concluded that – whilst characteristics of individual 
pharmacists would affect the implementation of cognitive services – internal, external and 
business/financial organisational factors (such as pharmacy design, utilisation of support staff, 
and use of technology internally and relationships with patients, prescribers and payers 
externally) needed further attention for effective incorporation into implementation processes. 
“New cognitive services should no longer be presented in the absence of a clear framework 
for how the service should be implemented”. 
 
Hallmarks of a model of innovative pharmacy practice (Canada) (Management 
Committee CPhA, 2008) 
 
Four indicators have been proposed as hallmarks of a model of innovative practice: 
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4 INFORMATION TECHNOLOGY 
 
4.1 TECHNOLOGY – QUANTITATIVE RESEARCH FINDINGS 
 
We asked participants to indicate what activities were supported by their computer system in 
the pharmacy. We asked whether the system they used had a feature relating to a range of 
activities, whether they made use of this feature, and whether they would like to do more of 
this by computer. The following table indicates the responses: 
 
Table 6: Computer System Features and Use 
Computer System Features and Use 
Have Feature in 
System 
Use Feature 
Would Like to 
Do More 
 Number Number Number 
Medicines Supplied 340 333 11 
Allergies Noted 311 323 34 
Interventions/Communications with Healthcare 
Professionals 
215 215 175 
Non-Prescription Items 129 95 235 
Drug Interactions 301 306 34 
Adverse Drug Reactions 248 241 103 
Adverse Incidents 111 112 255 
Pharmaceutical Care Needs 207 229 126 
Referrals to Other Healthcare Professionals 70 85 265 
Disability Support Given 92 96 241 
Advice on Minor Illnesses 40 36 305 
Healthy Lifestyle Interventions 30 20 305 
Patient Disease State 191 120 195 
General Comments 255 300 61 
Non-Clinical Incident Reporting 73 79 233 
Ordering Stock 296 324 16 
Providing Information to Patients 179 180 182 
CPD/Educational Activities 36 42 295 
Decision Support 114 133 232 
Supporting Professional Services 119 135 228 
Professional Networking 42 47 285 
Other 1 3 13 
 
Respondents were asked to indicate whether they recorded clinical information on paper, to 
which 37.6% said yes and 62.4% no. The types of information recorded included 
prescriptions, details on patients with complex medication regimes or those subject to 
significant changes, incident reporting, logs of phone calls and communications with other 
healthcare professionals, additional notes regarding patients that can‟t be logged on the 
computer, clinical interventions and dispensing errors, and daily audits. 
 
We asked pharmacies how many computers (i.e. PCs or laptops) were in the pharmacy; the 
average (mean) was 1.9, with the most common response being 2 and the maximum being 8. 
 
When asked to indicate which supplier the pharmacy‟s computer system was from, the two 
main responses were Helix Health (49%) and McLernon‟s (41.3%), with Ocuco at 9%. 
 
The vast majority of the computer systems (96.5%) are Windows-based. 
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Most pharmacy staff (78.6%) have access to relevant internet resources. Of those resources, 
the most popular is medicines.ie, with the IPU, PSI, HSE, and IMB websites also commonly 
accessed, as illustrated in the following table (the percentages add up to more than 100% 
because each respondent could select more than one option). 
 
Table 7: Internet Resources Used Most 
Internet Resources Used Most 
 Number Percent of Cases 
PSI 202 46.9% 
IMB 153 35.5% 
Medicines.ie 331 76.8% 
HSE 188 43.6% 
IPU 270 62.6% 
Patient Support Groups 108 25.1% 
Other Internet Resources 105 24.4% 
Total 1357 314.8% 
 
Other internet resources used include Google, poitigeir.com, UK sites such as patient.co.uk, 
NHS, and RPSGB, PubMed, NICE, and BNF online. 
 
We asked participants to indicate whether the pharmacy had an email address (66.5% did) 
and whether patients used this (only 17.1% said they did). We also asked if the pharmacy had 
a website, which 29.7% of respondents said they did. 
 
International Comparison Notes: 
 
The presence of having a pharmacy website was 11.1% in Australia for 2002 (Berbatis et al., 
2003). 
 
One-third of the pharmacists in England and Wales were using Internet information to advise 
the public (Blenkinsopp et al., 2007). 
 
4.2 TECHNOLOGY – QUALITATIVE RESEARCH FINDINGS 
 
4.2.1 Current and Future IT Infrastructure 
 
We asked the interviewees whether they were satisfied with their current IT set-up and 
whether they anticipated requiring changes to support current or future service provision. By 
far the vast majority of pharmacists we spoke to were entirely happy with their current 
IT infrastructure. Some expected that significant changes would be required to their current 
systems but, for many, any changes to accommodate new services would be relatively 
minor – add-ons or upgrades rather than complete new systems. 
 
4.2.2 Data Transfer between Healthcare Professionals and Pharmacists 
 
Pharmacists were asked whether they would like to see links with data held about their 
patients by other healthcare professionals. This question was interpreted differently by 
different pharmacists and overlapped somewhat with aspects relating to the interprofessional 
relationships with GPs and other healthcare professionals. 
 
In terms of the general principle, leaving aside the obvious concerns expressed in relation to 
data protection considerations and patient confidentiality, many pharmacists did feel that 
access to at least some patient data held by GPs and others would be helpful to their 
practice. Several commented that at a minimum, knowing the disease state and full diagnosis 
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of the patient would be very helpful in interpreting the prescriptions for that individual. Some 
mentioned the potential usefulness of knowing the latest test results for the condition (e.g. the 
latest blood pressure reading for someone on medication for high BP) so that they would 
know how well the medication was working. Full hospital discharge notes would also be 
helpful, many said. 
 
We also asked about information going the other way, i.e. from pharmacists to GPs and other 
healthcare professionals. Many mentioned compliance concerns as something they would like 
to share: if patients are not filling their prescriptions as they should, pharmacists feel that GPs 
should know as otherwise they may assume that a failure to control the condition requires a 
change in the medication rather than realising that it results from the patient not taking the 
original medication correctly. Pharmacists also mentioned passing on the information as to 
the full range of medications prescribed for a patient to hospital staff. 
 
Most pharmacists mentioned that such information is often exchanged on an informal basis in 
any case – if they have a query regarding the prescription and they need the diagnosis, then 
they ring the GP. Similarly, if the hospital rings asking for information on a patient‟s 
medication regime, they give the information out. Formalising this exchange would be 
welcomed by many, even in simple ways like using email to get around the difficulties in 
accessing the information in a timely fashion if the doctor or other healthcare professional is 
unavailable at the time. 
 
Some pharmacists suggested that a swipe card of some description might be a useful 
development, to keep a record of medications prescribed and dispensed, possibly including 
other details such as the diagnosis. This would help to maintain the information flow between 
pharmacists and prescribers, and would also address the problems that arise when patients 
use different pharmacies to obtain their medicines. 
 
International Vignette: 
Perceptions of the development of community pharmacy IT systems (Finland) 
(Westerling et al, 2010) 
 
This study compared the perceptions of owner pharmacists and frontline pharmacists 
regarding important features of IT systems. “The features related to the pharmacy‟s internal 
processes, such as financial management, sales and marketing management and stock 
holding, were ranked significantly higher by the managers, while the personnel prioritized the 
features supporting pharmaceutical service provision and personnel management. The 
managers and personnel shared their opinion on the importance of features supporting drug 
information and patient counselling, medication safety and inter-professional collaboration.” 
They conclude that managers and „staff‟ pharmacists have different needs of pharmacy IT 
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5 INTER-PROFESSIONAL RELATIONSHIPS 
 
5.1 INTER-PROFESSIONAL RELATIONSHIPS – QUANTITATIVE FINDINGS 
 
5.1.1 Referral Procedures 
 
Participants were asked whether they had referral procedures in place for following up on the 
outcomes of diagnostic screening services, to which 63% said they did have such services in 
place (of the 53% of those who answered the question). 
 
5.1.2 Relationship with Local Doctors 
 
We asked respondents to rate their satisfaction with the relationship with local doctors. The 
majority were either satisfied (32.2%) or very satisfied (28.2%) with the relationship, with just 
over a quarter (26%) saying they were neither satisfied nor dissatisfied, 7% dissatisfied, and 
4.2% very dissatisfied. The graph below illustrates this: 
 
Figure 12: Satisfaction with Local Doctor Relationship 
 
 
When asked if they had regular meetings with local doctors, a significant majority (87.6%) 
said they did not have such meetings. 
 
We asked pharmacists to indicate what other healthcare professionals they interacted with on 
a regular basis regarding patients‟ medication and other issues, and the following table shows 
the responses. Most indicated they had contact with hospital doctors, practice nurses, and 
hospital pharmacists, while few had interacted with nurse prescribers or opticians. 
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Table 8: Interaction with Health Professionals 
Interaction with Health Professionals 
Health Professionals No. Percent of Cases 
None 26 5.8% 
Consultant/Hospital Doctor 307 69.0% 
Practice Nurse 302 67.9% 
Nurse Prescriber 35 7.9% 
Other Nurse 154 34.6% 
Other Community Pharmacist 241 54.2% 
Hospital Pharmacist 284 63.8% 
Dentist 186 41.8% 
Optician 37 8.3% 
Social Worker 62 13.9% 
Other Healthcare Professional 24 5.4% 
Total 1658 372.6% 
 
 
We asked about engagement with local multi-professional groups and patient support groups, 
the majority had not had engagement with either. 94.6% of those who responded said they 
did not have engagement with local multi-professional groups, and the vast majority of 
respondents (91.6%) indicated they had no engagement with patient support groups. Of those 
who did, examples of multi-professional groups engaged with include local primary care 
teams and practitioners, palliative care teams, and prescribing advisory roles.  Examples of 
patient support groups engaged with include Aware, Irish Cancer Society, Irish Heart 
Foundation, Diabetes Foundation of Ireland, Asthma Society of Ireland, Arthritis Society, local 
groups such as elderly care and hospice support groups, Migraine Association, and Suicide 
Prevention. 
 
International Comparison Note: 
 
A European study showed 9.1% response for engagement with local multi-professional 
groups in Ireland in 2006, the lowest in the range across Europe which went up to 34.7% in 
Belgium (Hughes et al. 2010).  
 
5.2 INTER-PROFESSIONAL RELATIONSHIPS – QUALITATIVE FINDINGS 
 
5.2.1 Relationship with GPs and Other Healthcare Professionals 
 
We asked participants to describe their professional relationship with GPs and other 
healthcare professionals. Most pharmacists‟ main relationship is with the local GPs, and for 
the majority, this relationship is very good. In general, interviewees felt their interactions with 
their GPs were cordial, that the relationship involved mutual respect, that the communication 
was good, and that they could work together for patients‟ benefit. One suggested that this 
contrasted with her previous experience in the UK. 
 
A few mentioned difficulties with local GPs, with issues such as feeling that the GP didn‟t 
respect their role, or that queries from the pharmacist were regarded as criticisms of the GP‟s 
decisions. 
 
In terms of other healthcare professionals, this was a less significant feature for most 
pharmacists. They did suggest that their relationships with hospital pharmacists were good, if 
less involved than that with GPs, and that their only difficulties with hospital pharmacists or 
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doctors was the difficulty in accessing them: the former outside working hours and the latter at 
all times. Several mentioned trying to chase up queries with hospital staff for weeks at a time 
with little success in getting phone calls returned, etc. 
 
International Vignette: 
Changes in the community pharmacy contractual framework (CPCF) in England and 
Wales since 2005 – Inter-professional working (Blenkinsopp et al. 2007) 
 
In the year following the implementation of the new CPCF, only 18% of community 
pharmacists said that it had increased their involvement with GPs. 
 
5.2.2 Factors in and Barriers to Successful Inter-professional Relationships 
 
Interviewees were asked what factors they would consider important to the development of 
good relationships with other healthcare professionals. The main themes emerging in this 
area are as follows: 
 Mutual respect; 
 Communication; 
 Trust; 
 Acknowledgement, understanding, and recognition of each others‟ roles. 
 
Conversely, the barriers that can hamper the development of successful professional 
relationships included the following: 
 Lack of time; 
 Lack of understanding of or respect for the pharmacist‟s role; 
 Personality clashes; 




Collaborative Practice Agreements (USA) (Peacock et al, 2007) 
 
In this national survey of US pharmacists, 34% of those responding reported that at least one 
of their patient care services were provided under a „collaborative practice agreement‟: a 
collaborative practice agreement exists between one or more physicians and pharmacists, 
wherein qualified pharmacists working within the context of a defined protocol are permitted to 
assume professional responsibility for performing patient assessments; ordering drug 
therapy-related laboratory tests; administering drugs; and selecting, initiating, monitoring, 
continuing, and adjusting drug regimens. The most common agreements were for 
immunisations (58%), diabetes management (24%), and blood pressure monitoring (16%). 
The American College of Clinical Pharmacy has stated that collaborative practice is 
dependent upon “(1) a collaborative practice environment; (2) access to patients; (3) access 
to medical records; (4) knowledge, skills, and ability; (5) documentation of activities; and (6) 
compensation for their activities” . 
 
5.2.3 What Can Pharmacists Do? 
 
We asked what pharmacists could do to promote good relationships with healthcare 
professionals. Some suggested that building up a relationship over time by means of good 
communication, including communication over and above the absolute necessities of 
prescription queries, was helpful. However, some suggested that maintaining only 
professional communication about patients was key to not encroaching too much on GP time 
or becoming an annoyance. Several mentioned that pharmacists could and should personally 
introduce themselves to local GPs so that they could put a face to a name and not restrict 
contact solely to phone and fax. There were also suggestions such as sending out information 
to GPs about developments in medicines: new medicines or new information about existing 
products. 
  




Inter-professional factors and provision of Enhanced Pharmacy services (Australia) 
(Berbatis et al, 2007) 
 
Half of the Australian pharmacists in this national survey agreed that they had no time to meet 
with GPs and other health professionals, and that this was a barrier to providing enhanced 
services. A similar number agreed that GPs did not recognise pharmacists‟ enhanced service 
skills. The majority disagreed, however, that providing such services would damage 
relationships with local GPs. 
 
5.2.4 Role for PSI/Other Organisations 
 
When asked what role the PSI or other organisations could play in fostering good professional 
relationships between pharmacists and other healthcare professionals. While many did not 
see any wider context to their relationship with local GPs, believing it to be something based 
on individual interactions, some did have some suggestions as to what could be done on a 
national level to promote better pharmacist-doctor relationships, including the following: 
 Joint CPD and CE activities with doctors on appropriate topics, to bring the professions 
together; 
 The PSI should work together with the IMO and other doctors’ organisations to develop a 
greater appreciation of the role and qualifications of pharmacists and how they can 
support doctors; 
 The PSI should continue its emphasis on professionalising pharmacy and improving 
standards to maintain the message that pharmacy is a high-quality healthcare service; 
 The HSE should develop – as mentioned previously – a clear vision for pharmacy and 
how it fits within the healthcare system: without recognition at a national level, 
pharmacists feel it is difficult to promote themselves at a local level; 
 Integration of pharmacies into primary healthcare teams, both to bring pharmacists into 
formal arrangements with doctors and other healthcare professionals for the delivery of 













6.1.1 Number of Pharmacists 
 
We asked respondents how many pharmacists were working in the pharmacy. The average 
was 2, with a maximum of 5. It should be noted that this is not always indicative of full-time 
pharmacists and that many have indicated two pharmacists who may cover for each other 
and not work alongside each other on a day-to-day basis for much of the working day. 
 
International Comparison Note: 
 
In England and Ireland, provision of Pharmaceutical Care was more extensive when a higher 
number of pharmacists were employed (Hughes et al. 2010) 
 
6.1.2 Hours Worked in a Typical Week 
 
Respondents were asked to outline the typical weekly hours for each pharmacist in the 
pharmacy, the graph of which is shown below. It can be seen that the first pharmacist is 
generally full-time, with hours around 40-41 per week, while the hours for the second and 
subsequent pharmacists (apart from the sole example of the pharmacy with 5) indicating that 
they are part-time and often covering for opening hours when the first pharmacist is not 
working. 
 





Participants were asked to outline the role for each pharmacist in the pharmacy, the table of 
which is shown overleaf.  
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Table 9: Role of Each Pharmacist in Pharmacy 
Position 
 Supervising Pharmacist Superintendent Pharmacist Both Employee Locum 
 Number % Number % Number % Number % Number % 
Pharmacist 1 - Position 175 40.3% 32 7.4% 195 44.9% 25 5.8% 7 1.6% 
Pharmacist 2 - Position 18 5.2% 27 7.8% 11 3.2% 227 65.8% 62 18.0% 
Pharmacist 3 - Position 5 5.2% 8 8.2% 5 5.2% 54 55.7% 25 25.8% 
Pharmacist 4 - Position 2 11.8% 1 5.9% 1 5.9% 9 52.9% 4 23.5% 
Pharmacist 5 – Position 0 0.0% 0 0.0% 0 0.0% 1 100.0% 0 0.0% 
 PSI Baseline Study Final Report 
38 
6.1.4 Length of Time Qualified 
 
We asked respondents to indicate how long each of the pharmacists was qualified, with 
the averages for each pharmacist outline in the graph below: 
 
Figure 14: Length of Time Qualified 
 
 
6.2 OTHER STAFF 
 
6.2.1 Numbers of Other Staff 
 
Participants were asked to outline the numbers and categories of non-pharmacist staff in 
the pharmacy, as illustrated in the table below. The average number of pharmaceutical 
assistants was 0.7, with 1 being the most common answer; pharmacy technicians 
averaged 1.4 per pharmacy; counter staff 3; and other staff 1.3. 
 
Table 10: Numbers of Other Staff in Pharmacy 








Counter Staff Other Staff 
Number who 
responded 
235 165 335 418 140 
Missing answers 222 292 122 39 317 
Mean .72 .36 1.40 3.03 1.30 
Median 1.00 .00 1.00 3.00 1.00 
Mode 1 0 1 2 1 
Minimum 0 0 0 0 0 
Maximum 5 3 5 12 10 
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International Comparison Note: 
 
England, Northern Ireland and Ireland achieved higher scores on the validation of filled 
prescriptions when higher numbers of dispensing staff were employed (Hughes et al. 
2010). 
 
6.2.2 Hours Worked by Other Staff 
 
We asked pharmacists to indicate the typical total working hours of the non-pharmacist 
staff per week. The table below illustrates the responses: 
 
Table 11: Hours Worked by Other Staff 
Hours Worked by Other Staff 
 
Pharmaceutical 
Assistants - Total 
Hours 
Pharmacy Interns 




Counter Staff - 
Total Hours 




154 85 392 114 293 
Missing 303 372 65 343 164 
Mean 24.47 27.31 51.35 84.28 36.66 
Median 23.00 39.00 40.00 70.00 25.00 
Mode 0 40 40 40 40 
Minimum 0 0 0 0 0 
Maximum 80 150 162 480 360 
 
International Vignette: 
Factors associated with the provision of pharmacy services beyond dispensing 
(USA) (Doucette et al. 2006) 
 
In the US National Pharmacist Workforce study of 2004, four factors were associated with 
the provision of pharmacy services beyond dispensing were the number of pharmacists on 
duty; innovativeness (a 3-point self-perception subscale comprising reputation as an 
innovator among peers, promotion of new services, and providing leadership in services); 
being an independent pharmacy, and being a supermarket pharmacy. As most new 
services were being provided by between 10% and 20% of pharmacies, the authors 
concluded that nationally they were still in the „early adopter‟ stage of innovation. 
 
6.3 QUALITATIVE FINDINGS – WORKFORCE 
 
We asked participants what, if anything, they would change about the workforce in the 
pharmacy. Most responded that they would take on more staff, in an ideal (i.e. affordable) 
situation. For most, they would like to take on more qualified pharmacists, usually a full-
time second pharmacist for single-pharmacist pharmacies. A few felt that their staffing was 
fine the way it was; most of these already had more than one qualified pharmacist working 
in the pharmacy. 
 
International Vignette: 
Job Satisfaction (England/Wales) (Blenkinsopp et al. 2007) 
 
The three aspects of their job that English/Welsh pharmacists felt most satisfied about after 
the new contract were “colleagues and fellow workers”, “patient contact” and “amount of 
responsibility I am given”. The three aspects they felt least satisfied about were “respect 
received from GPs”, “remuneration” and “my role since the new contract”.  
The new contract received a mixed response overall among pharmacists regarding their 
future: “A substantial minority of pharmacists felt their job was less satisfying than before 
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the new contract (30%) and that they were now less likely to stay in community pharmacy 
(26%). Overall 17% said they were more satisfied and 19% that they were more likely to 
stay in community pharmacy”. 
 
Following up from this, we asked whether they would like a better ratio of pharmacists to 
other staff; almost everyone agreed that they would like this. We asked them to outline the 
benefits of this: from a workload point of view people were agreed that reducing the 
workload on the – usually single – current pharmacist would be welcome. Interviewees 
also highlighted the potential improvements in services to patients: more time to spend 
counselling, for example. As mentioned above, time and staffing restrictions were the most 
significant barriers to service development, so taking on more pharmacists would mean the 
ability to develop new services. 
 
Pharmacists were also very enthusiastic about the benefits arising from working alongside 
another professional pharmacist: almost everyone felt that this improved or would improve 
their own professional practice by challenging them and highlighting and filling in gaps in 
their own knowledge. They also felt that being able to confer with a professional colleague 
on queries or doubts they might have would again improve the service to patients and 
maintain high levels of patient safety. 
 
Most of those interviewed believed that their current staffing levels did not reflect what 
would be needed to expand or improve the services in their pharmacy. 
 
International Vignettes: 
Psychosocial determinants of implementing pharmaceutical care (Spain) (Zardaín et 
al. 2009) 
 
This study found that 11.8% of Spanish community pharmacists had implemented 
pharmaceutical care within their practice, and were in the action or maintenance stage of 
this particular behaviour change. As the stage of change of other pharmacists moved from 
pre-contemplation to action, scores relating to attitude, social influence of others and self-
efficacy increased. The factors positively associated with the probability of implementation 
of pharmaceutical care among Spanish pharmacists were “having undertaken appropriate 
training, self-efficacy, having assistant pharmacists, and positive attitude”. 
 
We asked about the way in which work was delegated to the non-pharmacist staff in the 
pharmacy. Most pharmacists stated that they delegated as much as possible within the 
regulatory constraints to their dispensary staff (technicians) and counter staff. Prescription 
preparation, stock control, paperwork as appropriate, ordering, etc. are all routinely 
delegated in most of the pharmacies concerned. Some pharmacists did not delegate 
aspects of paperwork that they would prefer to keep confidential from the point of view of 
being the business owner; a few in larger chains found that they were less busy than other 
pharmacies in the dispensary and so the need to delegate didn‟t arise as much. 
 
When asked why some pharmacists might not delegate as much as possible, most 
suggested that there was no particular reason why as much work as possible should not 
be given to the non-pharmacist staff. Some discussed the issue of trying to control 
everything and not believing that others could perform the tasks as well as themselves. 
Others mentioned that staff training might not have been up to date and therefore the staff 
were not yet capable of taking on certain tasks. 
 
International Vignette: 
Changes in the community pharmacy contractual framework (CPCF) in England and 
Wales since 2005 – Workforce (Blenkinsopp et al. 2007) 
 
Two-thirds of pharmacists reported delegating more work to non-pharmacist staff since 
implementation of CPCF, such as more input into running the core business (e.g. ordering 
stock, developing standard operating procedures, and accuracy checking of prescriptions) 
and clerical tasks associated with enhanced services (e.g. filing, completing initial patient 
information). One-quarter reported more delegation to other pharmacists. 
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7 CONTINUING PROFESSIONAL DEVELOPMENT/CONTINUING EDUCATION 
 
7.1 CDP/CE – QUANTITATIVE FINDINGS 
 
7.1.1 Staff CPD/CE 
 
We asked respondents to indicate what arrangements were in place for staff in the 
pharmacy to undertake CPD and CE activities. The graph below illustrates the responses. 
 
Figure 15: Arrangements for Staff CPD/CE 
 
 
Other arrangements included several responses to the effect that no arrangements are in 
place; others mention providing updates on developments in pharmacy and having 
reference material in the pharmacy for staff. Those who have minimum CPD/CE 
requirements outlined them most commonly having a minimum number of hours per year 
to simply being expected or encouraged to undertake CPD activities in general. 
 
International Comparison Note: 
 
A recent European study shows participation in CPD in Ireland at 78.9% in 2006, with a 
range across Europe from 25% in Iceland to 97.9% in Portugal. 
 
7.1.2 CPD/CE Activities Undertaken 
 
Participants were asked which types of CPD and CE activities they undertook. The 
following graph outlines the results, ordered according to which had the most responses: 
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Figure 16: CPD/CE Activities Undertaken 
 
 
International Comparison Note: 
 
In a recent European study, Ireland had 14% postgraduate qualification response in a 
range across Europe from 2.7% in Malta to 71.9% in Switzerland (Hughes et al. 2010). 
 
“Other” activities undertaken include training and supervising pharmacy technicians and 
delivering CPD/CE modules for the ICCPE and others. 
 
Postgraduate qualifications commonly included the MSc in Community Pharmacy from 
TCD, along with diplomas and certificates in community pharmacy from TCD and Queens 
University Belfast, and the Masters in Health Management from RCSI. 
 
7.1.3 Enablers and Barriers 
 
Respondents were asked what would enable them to undertake more CPD and CE, and 
what prevents them doing as much CPD/CE as they would like to undertake, selecting 
several options from a range offered. The following tables indicate the responses. 
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Table 12: CPD Enablers 
CPD Enablers Number Percentage 
Availability Closer to Pharmacy 266 60.2% 
Greater Frequency/More Convenient 
Times 
321 72.6% 
Enhanced Range of Topics 287 64.9% 
Online/Technology-Based Learning 288 65.2% 
More Locum Cover 128 29.0% 
Staffing Rosters 97 21.9% 




Other Enablers 31 7.0% 
Total 1780 402.7% 
 
“Other” enablers mentioned include financial issues – mainly reimbursement for locum 
cover or other subvention to facilitate attendance – and training during working hours (also 
mentioned is the need to be more family-friendly). 
 
Table 13: CPD Barriers 
CPD Barriers Number Percentage 
Lack of Time 370 83.9% 
Difficulties with Cover 151 34.2% 
Distance 201 45.6% 
Inconvenient Times 229 51.9% 
Insufficient Range 140 31.7% 
Lack of Information 65 14.7% 
Other Barriers 51 11.6% 
Total 1207 273.7% 
 
“Other” barriers outlined include time – related to the comment above – the long working 
hours and family pressures in respect of evening lectures, financial aspects of paying for 
cover and the costs of lectures, and the quality of the material delivered. 
 
International Vignette: 
Changes in the community pharmacy contractual framework (CPCF) in England and 
Wales since 2005 – CPD (Blenkinsopp et al. 2007) 
 
The barriers to undertaking CPD most often reported were lack of time and fatigue. 
Pharmacists were asked which topics they would like to cover for CPD and the results (in 
descending order of popularity) were: clinical topics; research/audit; clinical governance; 
health promotion/public health; structuring the consultation; IT; management; 
communicating with patients and carers; training/supervision; communication with other 
health professionals; and time management. 
 
The recommendations of the contract evaluation report included the following about CPD 
and reflective practice: 
 Use CPD facilitators to provide support for reflective practice and practice 
development; 
 Provide tools for reflective practice to underpin reflection on current ways of working 
and possible ways of changing; 
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 Secure, with other stakeholders, a practice development programme for community 
pharmacy; 
 Support the development of workload analysis and management tools for community 
pharmacy. 
 
7.2 CPD/CE – QUALITATIVE FINDINGS 
 
7.2.1 Opinion on Current CPD and CE Availability 
 
Interviewees were asked if they felt that the current CPD and CE activities available to 
them were equipping them for their current and future practice. 
 
There was mixed response to this. There was quite a varied opinion on the quality of the 
CPD and CE activities provided by the ICCPE; some pharmacists were quite happy with 
the content and the range of topics covered, while others rated the quality of the content as 
low and were unhappy with the information presented and how it was delivered. 
 
Many pharmacists were dissatisfied with the timing of the ICCPE lectures. Most suggested 
that the end of a working day is a difficult time to attend lectures, especially when for many 
this includes a significant commute to the venue. Interviewees suggested that full-day 
weekend or even weekday courses would be preferable to attending a number of late-
evening sessions. 
“The way they’re scheduled is really difficult to attend. They seem to be like, just from a practical 
point of view you can’t say, like, every Monday I can do this, you know: it might be a Monday one 
week and then a Wednesday four weeks later and a Thursday three weeks later all in different 
venues in different places, and that aspect of it is really irritating.” 
 
Many of those interviewed undertake their own CPD and CE activities, often using online 
resources. Several suggested that the ICCPE should expand into online CPD and CE 
provision to address the issues surrounding access to and time to undertake the current 
schedule of activities. 
 
7.2.2 Impact of Development of Services on CPD and CE 
 
There was near-universal agreement that future service development, especially into 
screening and diagnostic services, would require specific CPD and CE resources to 
support this. From specialised training courses in the delivery of new services, both for 
pharmacists and other pharmacy staff, to the validation of skills and assessment of 
competence to provide such services, interviewees all feel that new service developments 
will require to be underpinned by training and development. 
 
It was suggested that the PSI could play a role – as the body responsible for the standards 
within pharmacy – in relation to verifying and maintaining standards of competence for new 
specialist services. Many pharmacists said that they would like to see a certification or 
validation process for new services, so that only those who have completed the accredited 
training courses can deliver them. This was especially mooted in respect of pharmacist 
prescribing, which was recognised as something that would require very close monitoring 












The following map indicates the number of responses from each county: 
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8.1.2 Type of Pharmacy 
 
We asked respondents to categorise the pharmacy according to whether it was a single 
outlet or part of a small or big chain or group. Just over half were single-outlet pharmacies 
(52%), with small group or chain pharmacies representing 26.3% of the responses and 
large group or chain pharmacies representing 21.7%. 
 
International Comparison Note: 
 
A recent European study (Hughes et al. 2010, but data from 2006) showed slightly more 
responses from independent pharmacies for Ireland 64.4/15.3/20.0, and was in the middle 





Participants were asked to indicate whether the pharmacy was in a city, large town, mid-
sized town, small town, or village. City pharmacies were more common, with 27% of the 
responses, followed by mid-sized and small towns (almost even at 23.4% and 23% 
respectively), and then large towns (15.2%) and villages (11.4%). The following pie chart 
illustrates the split: 
 
Figure 18: Location 
 
 
International Comparison Note: 
 
Work in the US in 2005 showed a positive association between providing cognitive 
services and a more rural location (Gadkari 2009). 
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8.1.4 Physical Setting 
 
We asked where the pharmacy was located in terms of its setting, i.e. high streets, 
shopping centre, housing estate, small parade of shops, etc. Most (44.4%) were on a high 
street, with a neighbourhood parade of shops the next most common setting (28.5%). 
Shopping centres accounted for 16.1%, with “Other” at 7.4% and housing estates at 3.6% 
being the least common settings. 
 
8.1.5 Proximity to Healthcare Services 
 
Respondents were asked how far the pharmacy was from a range of other healthcare 
services. The table below illustrates the responses: 
 
Table 14: Proximity to Healthcare Services 
Proximity to Healthcare Services 
 
<500m 501m to 1km >1km 
Number % Number % Number % 
Acute Hospital 24 5.6% 64 15.0% 339 79.4% 
Private Urgent Care Centre 27 7.6% 39 11.0% 289 81.4% 
GP Surgery 305 68.4% 107 24.0% 34 7.6% 
HSE Health Centre 80 20.8% 124 32.2% 181 47.0% 
HSE Primary Care Centre 31 9.3% 54 16.1% 250 74.6% 
 
8.1.6 Length of Time Pharmacy Established 
 
The average length of time that pharmacies in the survey were established was 32.8 
years, with a maximum of 161 years and a minimum of 0.08 years. 
 
8.1.7 Opening Hours 
 
We asked respondents about their opening hours, beyond the normal business hours. The 
following graph illustrates the extent of extended pharmacy opening hours: 
 
Figure 19: Opening Hours 
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8.2 PATIENT PROFILE 
 
Pharmacists were asked to outline what percentage various different groups of patients 
comprised their patient profile. On average, older patients made up 60% of respondents‟ 
patient profiles, with families with young children representing 26.7%, younger patients 
(12-30) making up 16.2%, and patients in residential care 5.4%. Pharmacists indicated that 
repeat or regular patients make up 78% on average of the pharmacy patient profile. 
 
8.3 CONSULTATION ROOM 
 
8.3.1 Consultation Room Installed 
 
We asked respondents whether they had the consultation room installed (notably now a 
legal requirement but this was not yet the case at the time of the survey). 73% of those 
who responded stated that their consultation room was in place at the time. 
 
International Comparison Note: 
 
A recent European study showed an Ireland response of 55.8% in 2006, in a pan-Europe 
range from 18.8% in Belgium to 85.8% in Portugal (Hughes et al. 2010). 
 
8.3.2 Number of Consultations 
 
According to the respondents, on average 9 consultations take place per week in the 
consultation room. 
 
8.3.3 Other Practitioners 
 
We asked if pharmacists allowed other healthcare practitioners to use the pharmacy 
premises for their services. Most did not (82.8%), with 17.2% stating that they did allow 
such practitioners to use the pharmacy.  Examples of other healthcare professionals and 
activities using pharmacy premises include chiropodists/podiatrists, opticians, audiologists 
and hearing-aid fitting, nurses performing screening activities, wig clinics, and 
nutritionists/dieticians. 
  




Flexibility and the implementation of services (Australia) (Feletto et al. 2010) 
 
This paper categorised community pharmacies in Australia as follows: 
 
Table 15: Types of Community Pharmacies in Australia 
Pharmacy Type Features 
Classic community pharmacy 
 Small in physical size 
 Service provision not the emphasis, and often outsourced 
 Viability depends upon the dispensary 
Retail destination pharmacy 
 Larger size with a wide range of health and non-health 
products 
 Service provision was not a strategic focus 
 Retail efficiencies and focused use of technology 
Health care solution pharmacy 
 Professional service provision was a focus 
 Differentiating themselves from other models of pharmacy 
through services, often to ward off competition 
 More staff employed to increase capacity, and complex 
training programmes 
 High use of technology 
 Teamwork focus, with a committed pharmacy owner 
Networked pharmacy 
 Small co-operative groups of pharmacies 
 Broad range of products and services, and cost-sharing 
 Service provision was a focus, sometimes strategically split 
across the pharmacies to create capacity and respond to 
local need 
 Use of technology very important to maintain control 
 
The authors concluded that this pharmacy „mix‟ was suggestive of a market undergoing 
relatively rapid evolution. It emphasised the impact in local environments of business 
changes i.e. the introduction of a price-focused pharmacy in an area might stimulate 
neighbouring pharmacies to concentrate on services: “Change in the local environment 
was seen to have a direct impact on effecting change in the philosophical standpoint of 
the owner and business model used.” They also concluded that „health care solution 
pharmacies‟ were best placed to integrate services. 
 




We asked interviewees to describe their catchment area and to outline whether it 
represented an area with disadvantage or affluence. Most commented that there was a 
mix in the area; some had quite high affluence; others had more than 90% GMS patients, 
indicating a significant level of disadvantage in the area. 
 
Several noted that they had recently seen a change in the economic circumstances of 
their patient profile, with an increase in GMS patients resulting from the impact of the 
recession on household incomes. 
 
8.4.2 Changes to Premises 
 
Pharmacists were asked if they would like to make changes to their premises in future, 
especially in light of potentially developing new pharmacy services. All the pharmacists 
either had recently installed or were in the process of installing the required consultation 
areas; many had undergone complete refits within the previous five years and were 
consequently not planning any further changes. 
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In terms of future service provision, many felt that their premises were adequate, especially 
with the consultation area in place. Others felt that further expansion or improvement 
would be necessary, especially in relation to specific aspects such as sterile conditions for 
certain diagnostic or monitoring procedures. The existing consultation areas would be too 
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We found that some of the questions and responses in both the survey and the interviews 
related more broadly to pharmacy in general and/or the organisations involved rather than 
specific to the aspects covered by the domains in the previous sections. 
 




We asked pharmacists who completed the survey to indicate their opinion on current 
pharmacy practice in Ireland and how they would like to see it develop into the future. A 
number of key themes emerged from the responses. 
 
9.2.2 Development of the Pharmacy Role 
 
One key issue that is clear from the responses to this free-text question is the role of the 
pharmacist and how that could and should be expanded. Many respondents felt that the 
pharmacist is currently under-utilised and that there is potential to expand the role of 
pharmacy in healthcare services to patients. Screening and diagnostic services, medicine 
use reviews, minor ailment schemes, vaccinations and similar services are suggested as 
ways for the pharmacist to contribute more to patient care. Several commented on how 
these kinds of services are well-developed in the UK and that Ireland was “behind” other 
countries in the development of such enhanced services. 
 
Related to this is the perception that pharmacy is under-valued and under-appreciated in 
the current healthcare structure. There were comments that the HSE regarded pharmacies 
as “vending machines” for medicine dispensing and were unwilling to view them in any 
other way. 
“Pharmacy presently not valued by government.” 
“Presently limited and primarily viewed as a dispensing practice with less recognition of our health 
professional knowledge.” 
“Underutilised; not regarded highly by the HSE.” 
 
Several mentioned the wish to see pharmacist prescribing and/or the movement of several 
medicines from prescription-only to OTC status. 
“Would like to see more pharmacist prescribing for minor ailments.” 
“I would like to see the movement of more POM to P medicines as in the UK, but I think pharmacists 
need to have appropriate training and perhaps accreditation to provide these products.” 
 
The issue of remuneration – the current structure and potential future changes – is 
important in relation to the development of new services, with comments to the effect that 
without adequate additional income, such services cannot be developed in community 
pharmacies. Time is also mentioned as a barrier to developing such services. 
“I am concerned that low remuneration levels in the future will restrict the development of improved 
professional practice.” “I would love to provide other services in-shop but due to time and money 
constraints, couldn’t see that happening.” 
 
9.2.3 Concerns about Regulation and Administration 
 
There were many comments describing the sense that the regulatory environment has 
become very pressurised and many perceive the regulations as excessive and 
unnecessary. This is exacerbated by the increasing burden of administration relating to 
reimbursement for patient services from the State. Some are concerned that the 
paperwork requirements are taking from the time for patient care. 
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“Drowned by a flood of bureaucracy and form filling.” 
“More emphasis on patient care rather than more guidelines and paperwork and having the 
pharmacist so tied up completing forms and paperwork that they have little or no time to talk to 
patients.” 
 
9.2.4 Feeling Under Pressure 
 
Many of the comments in response to this question referred to a time of intense pressure 
on pharmacy and pharmacists. Financial pressure and the difficulties in the relationship 
with the State feature strongly. There is uncertainty among many pharmacists as to how 
things will develop, making it difficult for them to plan and have stability. 
“I view it as a difficult environment at the moment financially.” 
“We are holding on by a thread.” 
“Undergoing a very difficult period with cutbacks and regulations.” 
“Under attack from the government.” 
“Difficult to commit to commit to providing additional services/changing shop to accommodate these 
services when HSE payments issue is still unresolved/uncertain.” 
 
9.2.5 Integration with Primary Healthcare Provision 
 
There were several responses with a desire to see closer integration of pharmacy into the 
primary healthcare structure, working more closely with GPs and other healthcare 
providers in a multi-disciplinary team set-up. 
“Collaboration with fellow healthcare professional under a primary care umbrella.” 
“We are an underutilised resource within the healthcare group.” 
“I would like to see more involvement of pharmacists in primary care teams.” 
I would like to see pharmacists educated and become part of a multi-disciplinary team.” 
 
9.3 PSI AND OTHER ORGANISATIONS –THEMES FROM QUALITATIVE INTERVIEWS 
 
When we asked pharmacists to discuss the potential role of the PSI and other 
organisations in respect of specific areas such as supporting service development or inter-
professional relationships, this opened discussion in some cases on the overall 
perceptions about the current and future role for the PSI and other organisations. 
 
There was a very wide range of opinion in relation to the PSI‟s current role and activities. 
For example, when we asked what the PSI could do to support pharmacists in developing 
new services, many interviewees questioned whether the PSI had any role in this regard, 
given its status as the industry regulator. Some questioned whether there might be a 
fundamental conflict of interest in having one organisation setting and enforcing standards 
on one hand and developing and promoting the sector on the other. Many felt that the 
current role of the PSI as regulator effectively took it out of any supportive role it might 
have played in the past. 
 
“I am confused as to how the PSI is considering how they are going to help us expand our services 
because at this stage now I consider it a regulator and nothing else.” 
“I don’t think that the Pharmaceutical Society has any input into expanding our professional roles. I 
think they are regulatory and they are there to control what’s going on and ensure that the rules are 
kept.” 
 
Several were unhappy with how the PSI has taken up its role as regulator, and the pace of 
change in relation to the Pharmacy Act and the new regulatory environment. Many referred 
to being bombarded with one new requirement after another and to feeling that the 
administrative burden has increased significantly in recent years. It was suggested that the 
PSI appeared to be concerned with details rather than the “big picture” in relation to the 
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practice of pharmacy. Some referred to the fact that there are aspects of pharmacy 
practice in terms of providing a high-quality service to patients that cannot be measured. 
 
“I personally think the PSI are putting huge pressure on us at a time where we’re getting pressure 
from every other side anyway. That if they kind of aided us rather than pressurised us to get where 
we want to go I think we would actually get there a lot faster.” 
“However, in my opinion following rules and regulations may make you a professional but it does not 
make you good at your job. I feel that they are missing out on what the art of pharmacy actually is.” 
 
However, this view was not universal. Many believe that the enforcing of standards was 
long overdue and that the pharmacy sector overall is benefiting from the increase in 
standards and enforcement, ensuring that everyone is meeting the professional standards 
necessary to maintain a high quality service to patients. Some were supportive of the 
overall aims of the PSI‟s programme of activities even if they did not agree with every 
aspect of the PSI‟s actions over the past few years. 
 
“I think the guidelines that they are bringing in at the moment with regard to codeine and putting in 
consultation areas, I think that’s a very positive thing. A lot of pharmacists might not be thinking that 
but I do think it’s a good thing, I think it’s a great thing and you know because the inspections are 
coming along I think that you have to have everything right which is a good thing.“ 
 
The IPU was broadly supported as an organisation promoting the interests of pharmacists; 
however, many characterised it as being too focused on the financial aspects rather than 
the professional development of pharmacy and pharmacists. 
 
A few pharmacists suggested that there was room within pharmacy for a third organisation 
dedicated to the development of pharmacy as a profession; perhaps in conjunction with the 
academic institutions. 
 
“There is room for the three pharmaceutical colleges in Ireland to create a society which will embrace 
professionalism while at the same time allowing room for innovation.”  
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10 CONCLUSIONS AND RECOMMENDATIONS 
 
10.1 OVERALL CONCLUSIONS 
 
This Baseline Study has sought to provide an understanding of the nature and type of 
community pharmacy services currently being delivered in Ireland, and to compare current 
practice in Ireland with relevant aspects of community pharmacy in other developed 
countries. 
 
We have produced a comprehensive set of findings across a series of domains, each of 
which has been detailed in the preceding sections of this report. One significant aspect 
which proved to be difficult to achieve during the study was the production of like-for-like 
comparisons between Ireland and other countries, given the lack of commonality between 
healthcare systems, the absence of common definitions, and the differing legislative and 
regulatory regimes. Whilst we have been able to produce a series of relevant vignettes and 
other research findings within this report which do provide interesting comparisons 
between community pharmacy in Ireland and that in other countries, it may be that the PSI 
will wish to commission additional comparative research on specific topics as a result of 
our findings. 
 
Notwithstanding the issues surrounding comparative international research, some of the 
key strategic issues to emerge from this research have included the following: 
 
 A key factor that emerged in relation to pharmacists' opinions on how pharmacy 
should develop was the common perception that there is no national vision for 
pharmacy and how it could and should fit into the wider healthcare delivery system. 
This is something which the PSI could be seen to address by continuing to work 
closely with the HSE and Department of Health and Children. There is a strong sense 
within community pharmacy that the various bodies act in isolation and that there isn't 
a coherent strategy. 
 It would be worthwhile to examine ways to address the appetite for the provision of 
enhanced services, especially screening and diagnostic services, given the 
substantial body of positive responses to the "Would Like to Provide" questions for 
these services, where pharmacists have indicated that they don't currently provide 
them but would like to offer them to patients. 
 Further examination of the issue of medicines use reviews and pharmacist prescribing 
schemes may be merited, given their prominence in both the survey (80% would like 
to provide MURs) and the interviews, where both of these issues were key themes in 
what pharmacists want to see in community pharmacy in the future. 
 When looking at the development of further services, it would be helpful to take into 
account the influencing factors, such as the age of the supervising pharmacist and the 
location of the pharmacy in terms of city, small town, etc., identified by Dr John 
Newell's analysis and to focus on ways to encourage those who are under-
represented to be able to provide such services. 
 The PSI might consider looking at how it can support pharmacists in developing new 
services.  Potential mechanisms include the development of standards, the design of 
specific training programmes, and accreditation for "specialist" pharmacists to ensure 
that enhanced services are delivered according to specified standards. 
 Some of the data contained in this report has been superseded by the imminent 
development of, for example, mandatory CPD requirements and the establishment of 
the Institute of Pharmacy (see Section 10.2 below); readers will therefore note that 
some of the data reported herein is now historical, and the PSI will no doubt wish to 
consider our findings as part of the implementation of these new arrangements. 
 
  
 PSI Baseline Study Final Report 
55 
10.2 THE CHANGING CONTEXT FOR THE PSI 
 
As noted above, the PSI has been actively pursuing the strategic development of several 
areas of its responsibilities since this Baseline Study was initiated, with the result that 
some of the findings reported herein have been superseded by events external to this 
project. 
 
Central to this has been the matter of Continuing Professional Development (CPD). A core 
function of the PSI includes the requirement to promote and ensure a high standard of 
education and training for persons seeking to become pharmacists, and that those persons 
and pharmacists obtain appropriate experience. The PSI must also ensure that 
pharmacists undertake appropriate CPD, including the acquisition of specialisation. One of 
the PSI‟s main duties is the accreditation of education regimes for pharmacists, both prior 
to and post-registration. A further key duty is the requirement to take suitable action to 
improve the profession of pharmacy. 
 
The PSI recently commissioned studies to review the 5 year programme of education and 
training required to qualify as a pharmacist and the associated accreditation system (in 
August 2008) and to review international CPD models to determine an appropriate system 
of CPD for pharmacists in Ireland (in January 2009). The final reports were approved by 
the PSI Council at its June 2010 meeting. 
 
The PSI now wishes to proceed with the implementation of the recommendations arising 
from these two studies, in order to ensure a competency based approach to development 
that extends across both pre-registration and ongoing registration systems. With regard to 
the latter, the CPD review recommends the establishment of “an Institute overseeing the 
management and delivery of CPD, funding and supporting appropriate provision and 
ensuring outcomes are generated by providers and assessing the practice standards of 
pharmacists”. 
 
The Institute will also be required to contribute to the PSI‟s core duty of taking suitable 
action to improve the profession of pharmacy and the development of pharmacy practice in 
Ireland in line with international evidence and experience, and evolving healthcare needs, 
and to progress the Pharmacy Ireland 2020 initiative of the PSI Council. 
 
In order to manage the implementation and on-going management of the CPD programme 
allied with the development of pharmacy services, the PSI has recently commenced a 
procurement exercise to appoint an external body to take responsibility for the 
establishment of this Institute. It is also intended that the contract will include the 
appointment of an Institute Executive Director to manage the Institute overall, and a 
Director of Pharmacy Practice Development to oversee the development of pharmacy 
services.  
 
This very recent development is not reflected in the findings of the Baseline Study, nor 
indeed would respondents to the quantitative survey or qualitative interview participants 
have been aware of the conclusions and recommendations arising from the two reviews of 




As this is a Baseline Study, we have deliberately kept our recommendations to a minimum, 
confining them to the process of surveying the community pharmacy sector in future years, 
moving forward from this 2010 baseline. 
 
In essence, what we have produced is a snapshot of the pharmacy sector as it currently 
stands in 2010. This report does not attempt to identify trends, as that would require the 
production of data within common data sets over a period of time, and the measurement 
and analysis of any identified changes. However, we recommend that there would be 
considerable merit for the PSI to repeat this survey (both quantitative and qualitative) in 
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2015, to track any changes which have occurred in the intervening four years so that 
trends can be identified, changes in practice and perception tracked, and the impact of 
interventions or initiatives assessed. 
 
More immediately, the PSI may wish to commission further work on some or all of the key 
themes which have emerged from the Baseline Study, possibly including the topics set out 
in Section 10.1 above. Additionally, the PSI and Steering Group may wish to consider 
whether some of the international comparisons provided in this report via the vignettes are 
worthy of further exploration in the future. 
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BASELINE STUDY OF COMMUNITY PHARMACIES 
 
 
The Pharmaceutical Society of Ireland have commissioned this survey of community pharmacies in order to 
establish a baseline in respect of community pharmacy in Ireland and to build upon the information gathered 
to further develop the pharmacy sector in the future. 
 
Horwath Bastow Charleton is undertaking this survey on behalf of PSI. 
 
Responses to this survey will be anonymised and collated for the purposes of reporting and no identifiers will 
be passed to the PSI in respect of individual survey responses. 
 
Please return the survey by post before the 16th of July 2010 to: 
 
Vanya Sargent 





This survey is also available in online format. Should you wish to complete the survey online, please contact 





01 448 2253 or 01 676 0951 
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About you 
 
1. What is your designated role? [Please tick one] 
 
 Superintendent Pharmacist 




2. How would you best describe your position in this pharmacy? [Please tick one] 
 
 Owner  
 Manager 
 Other Permanent employee 
 Other, please describe: ______________________________ 
 
 
3. How long have you worked in this pharmacy? (please tick one) 
 
 Less than one year 
 One to two years 
 Three to four years 
 Five or more years 
 
 





5. Do you do any pharmacy-related activity other than that which relates to this pharmacy? 
 
 Yes   No 
 
 
5a. If Yes, please give details: 
 
___________________________________________________________________ (free text) 
 
 






7. Which age group are you in? 
 




 65 and over 
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 Northern Ireland School of Pharmacy 
 Other UK School of Pharmacy (Eng, Scot, Wales) 
 Other EU School of Pharmacy 
 School of Pharmacy outside the EU 
 Other (please specify) ______________________ 
 
 
10. What areas of pharmacy have you practised in since qualifying? [Tick all that apply] 
 




 Other (please specify) ______________________ 
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Services 
 
11. How many prescription items are dispensed in the pharmacy in a typical month? [Please tick one] 
 
 Less than 500 
 501 – 1000 
 1,001 – 2,000 
 2,001 – 3,000 
 3,001 – 4,000 
 4,001 – 5,000 
 5,001 + 
 
 
12. How many items in each of the following categories are dispensed in a typical month? 
 



















13. Does this pharmacy provide services to patients in residential care settings? 
 
 Yes   No 
 
 
13a. If Yes, then please tell us about the settings this pharmacy serves. 
 



























(older patients) ______ ______ 
    
Other residential care homes 
(e.g. for intellectual disability) ______ ______ 
    
Prisons ______ ______     
Homeless hostels ______ ______     





_______________________ ______ ______ 
    
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14. Do you provide any of the following enhanced services? For each service listed, please tell us whether you 
provide them now, or whether you would like to provide these services in future. [Tick all that apply] 
 
[An enhanced pharmacy service refers to a service implemented in pharmacies that is additional to or not routinely 
provided with prescribed or non-prescribed medicines. The service is often characterised by facilities and/or 
devices dedicated to the service and staff who are competent or formally trained and for which a private fee may or 
may not be charged.] 
 
Services Provide currently If not provided 
currently, would 
like to provide in 
future 
If not provided 
currently, would 
not like to 
provide in future 
Disposal of unwanted medicines    
Monitored dosage systems (not care homes)    
Home delivery service    
Supervised methadone service    
Needle exchange    
Fertility Treatment Dispensing Services    
Veterinary Pharmacy Services    
Advice and supply to residential care homes    
Palliative care    
Structured Medicine Use Reviews    
 
 
15. Do you provide any of the following health promotion services? For each service listed, please tell us 
whether you provide them now, or whether you would like to provide these services in future. [Tick all that 
apply] 
 
Health Promotion Services Provide currently If not provided 
currently, would 
like to provide in 
future 
If not provided 
currently, would 
not like to 
provide in future 
Structured smoking cessation services    
Nutrition / exercise    
Obesity / Weight management    
Sexual health    
 
16. Do you provide any of the following health screening services? For each service listed, please tell us 
whether you provide them now, or whether you would like to provide these services in future. [Tick all that 
apply] 
 
Health Screening Services Provide currently If not provided 
currently, would 
like to provide in 
future 
If not provided 
currently, would 
not like to 
provide in future 
Blood pressure screening    
Lipid / Cholesterol screening    
Diabetes screening    
Weight / Height / BMI screening    
Lung capacity screening    
Osteoporosis screening    
Pregnancy testing    
PSA (Prostate Specific Antigen) screening    
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17. Do you currently provide or wish to provide any other enhanced services not mentioned above? If so, 
please give details of these services 
 
Other Enhanced Services Provide currently If not provided 
currently, would 
like to provide in 
future 
____________________________________________________   
____________________________________________________   
____________________________________________________   
____________________________________________________   
____________________________________________________   
 
 
18. Please estimate the time that you (the pharmacist) spend on these activities during a typical week and 
indicate whether they take up time outside your normal working hours. 
 
 Tick one of the categories below Tick if it 
happens 



















Dispensing prescriptions        
Counselling prescription patients       
Counselling non-prescription patients       
Giving advice about minor illness       
Giving advice about long-term 
conditions 
      
Giving advice about healthy lifestyles       
Providing other pharmacy services 
in the pharmacy e.g. medicine use 
reviews 
      
Providing other pharmacy services 
outside the pharmacy, e.g. advice 
to care homes 
      
Communicating with other 
healthcare professionals 
      
Attending health related meetings 
e.g. HSE, patient support group, 
inter-professional meetings, etc. 
      
Undertaking CPD / training / ICCPE 
activity 
      
Audit (e.g. developing and reviewing 
SOPs) and Practice Research 
      
Adverse drug reaction reporting/ 
follow up 
      
Helping patients with their eligibility 
for state support with medicine costs 
      
Stock management e.g. ordering / 
sourcing and checking of medicinal 
products 
      
Other administration/management 
duties 
      
Staff training        
Merchandising        
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 Tick one of the categories below Tick if it 
happens 



















Breaks (e.g. lunch)       
Out-of-hours availability to patients 
(e.g. phone calls) 
      
Other (please specify) 
 
____________________________ 
      
 
 
19. What forms of written or non-verbal information/ counselling (e.g. direction to websites or support groups, 
providing leaflets, etc.) does the pharmacy offer to patients?  
 
 
___________________________________________________________________ (free text) 
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Technology 
 
20. Which pharmacy activities are supported by a specific feature on your computer system, and do you use 
this feature to record activity? [Tick all that apply] 
 
Categories My computer 
system has a 
feature that 
supports this 
I use this feature 
on my computer 
system 
I would like to do 
more of this by 
computer 
Medicines supplied    
Allergies noted    
Interventions and communications with other 
healthcare professionals 
   
Non- prescription items purchased    
Drug interactions    
Adverse drug reactions    
Adverse incidents (e.g. Prescribing or 
dispensing errors) 
   
Pharmaceutical care needs (e.g. medication 
must be supplied in MDS) 
   
Referrals to other healthcare professionals    
Disability support given (e.g. Non-child 
resistant containers) 
   
Advice on minor illnesses    
Healthy lifestyle interventions    
Patient disease state    
General comments on patients    
Non-clinical reporting of incidents in the 
pharmacy 
   
Ordering stock    
Providing information about medicines and 
health to patients (e.g. printing out 
information) 
   
CPD/educational activities    
Decision support (e.g. access to scientific 
papers, online reference sources) 
   
Supporting professional services (e.g. 
record-keeping, audit) 
   
Professional networking (e.g. pharmacy 
discussion groups) 
   
Other (please specify) 
 
____________________________ 
   
 
 
21. Do you record any clinical information on paper?  
 
 Yes   No 
 
 
21a.If yes, please describe what information is held this way. 
 
___________________________________________________________________ (free text) 
 
 
22. How many PC/laptop computers do you have in the pharmacy that are used for clinical pharmacy activities? 
 
________ (number) 
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23. Please tell us which computer supplier system you use: 
 
 Helix Health  
 McLernons 
 Ocuco 
 Other (please specify) _________________________________ 
 
 
24. Is the system based on Windows? 
 
 Yes   No 
 
 
25. Do the pharmacy’s professional staff have access to relevant healthcare resources on the internet from the 
pharmacy computer system? 
 
 Yes   No 
 
 
26. Which internet resources do you use most? [Tick all that apply] 
 
 PSI  
 IMB 
 Medicines.ie (IPHA)  
 HSE 
 IPU 
 Patient support groups 
 Other (please specify) _________________________________ 
 
 
27. Does the pharmacy have a dedicated pharmacy email address for professional pharmacy business which all 
pharmacists can access if necessary? 
 
 Yes   No 
 
 
28. Do patients ever email the pharmacy at this address? 
 
 Yes   No 
 
 
29. Does the pharmacy have a website? 
 
 Yes   No 
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Interprofessional Relationships 
 
30. If you offer screening services, do you have referral procedures to other healthcare professionals in place, 
where appropriate? 
 
 Yes   No 
 
 
31. Please indicate how satisfied you are with your professional relationship with local doctors for the purpose 
of providing patient care. 
 
Circle a number where 1 is very dissatisfied and 5 is very satisfied 
 
1 2 3 4 5 
 
 
32. Do you participate in meetings with any local GP practice(s) or other doctors’ groups? 
 
 Yes   No 
 
 
33. Other than GPs, which professionals do you regularly communicate with about a patient’s medication and 
other issues such as blood tests, screening and other health-related issues? [Tick all that apply] 
 
 None 
 Consultant (or other hospital doctor) 
 Practice nurse 
 Nurse prescribers 
 Other nurses 
 Other community pharmacists 
 Hospital pharmacist 
 Dentist 
 Optician 
 Social worker 
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Workforce 
 





35. Please tell us about the pharmacists that work in this pharmacy. 
 
Pharmacist (complete one 
line for each pharmacist 
that works at this 
pharmacy) 
Number of hours worked in a typical 
week in this pharmacy 























































      
2 
      
3 
      
4 
      
5 
      
6 
      
7 
      
8 
      
9 
      
10 
      
* If pharmacist is both Supervising and Superintendent Pharmacist, tick both applicable boxes 
 
36. Thinking about a typical week in your pharmacy, please tell us how many of the following members of staff 
work in the pharmacy (or pharmacy part of the business), including full-time and part-time staff: 
 
Staff role 
Number of individuals in the 
category 
 Total number of hours 
employed (week) 
Example 2  
65.5 
(35.5 for one / 30 for the other) 
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37. Do you or your pharmacists have any additional pharmacy qualifications or a speciality in a particular field 
within healthcare?  
 
Area in which you/they 
hold qualification(s) / 
specialise 
Qualification(s) or specialities 
e.g. Certificate, Diploma, MSc, PhD, other... 
Do you/they use this in 
your/their work? 
Yes No 
    
    
    
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Education/CPD (incorporating CE) 
 
CPD is defined as a systematic, ongoing, cyclical process of self-directed learning and continuous quality improvement 
which allows pharmacists to learn and develop to meet their own personal and professional needs, the needs of the 
health service and the needs of patients. CE is defined as structured formal learning experiences and activities that 
pharmacists undertake following registration to improve knowledge, skills and competencies. Quality-assured CE is a 
component of the learning experiences required in a CPD system. 
 
38. What arrangements have been put in place by the pharmacy owner and/or Superintendent Pharmacist to 
ensure all pharmacists employed maintain appropriate experience in the practice of pharmacy and 
undertake CPD (incorporating CE)? 
 
 Allowing paid time off for CPD (incorporating CE) activities 
 Allowing unpaid time off for CPD (incorporating CE) activities 
 Paying for staff membership of ICCPE 
 Funding CPD (incorporating CE) activities 
 Requiring pharmacists to undertake minimum levels of CPD (incorporating CE) (give details below) 
 Providing inhouse training and development activities 
 Providing a staff study area within the pharmacy 
 Other (please specify) _____________________ 
 
 
38a. If you have minimum CPD (incorporating CE) requirements for your pharmacists, please give details of 
these requirements below: 
 
___________________________________________________________________ (free text) 
 
 
This section refers to the pharmacist completing the questionnaire. 
 
39. What type/s of CPD (incorporating CE) activity have you done in the last year? [Tick all that apply] 
 
 Addressing learning opportunities in my everyday practice 
 Attending ICCPE lectures 
 Attending formal lectures by other providers 
 Attending other educational meetings 
 Reading professional journals 
 Reading scientific papers 
 Engaging in distance learning 
 I am working towards a postgraduate qualification: Qualification type ________________ 
 
       Institution  ________________ 
 Supervising pharmacy intern 
 Audit (e.g. developing and reviewing SOPs) 
 Other (please specify) ______________________________ 
 
 
40. Are you recording your CPD (incorporating CE) activity in a portfolio or similar? 
 
 Yes   No 
 
 
41. For what purposes have you undertaken CPD (incorporating CE)? 
 
 Personal professional development  
 To deliver a specific service in the pharmacy 
 Development of pharmacy staff 
 Developing interprofessional relationships 
 Other (please specify) ______________________________ 
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42. What would help you to engage in more CPD (incorporating CE)? 
 
 Availability of CPD (incorporating CE) activities closer to pharmacy location 
 Greater frequency and a more convenient range of times for CPD (incorporating CE) activities 
 Availability of an enhanced range of topics that meet practice needs 
 More access to online or technology-based learning methods for CPD (incorporating CE) 
 Greater availability of locum cover 
 Different staffing rosters in the pharmacy to free up time 
 Understanding what workplace activities can constitute appropriate CPD (incorporating CE) 
 More opportunities to engage in interprofessional learning with other healthcare professionals 
 Other (please specify) ______________________________ 
 
 
43. What stops you engaging in as much CPD (incorporating CE) as you would like to? 
 
 Lack of time 
 Difficulty arranging locum or in-house cover 
 Distance from CPD (incorporating CE) activities 
 Inconvenient times for CPD (incorporating CE) activities 
 Insufficient range of CPD (incorporating CE) activities for my needs and wants 
 Lack of information on what CPD (incorporating CE) activities are available 
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45. Type of pharmacy (Please tick one) 
 
 Single outlet 
 Group or Chain ownership with 2-5 outlets 
 Group or Chain ownership with 6 or more outlets 
 
 
46. Location (Please tick one) 
 
 City (pop greater than 30,000) 
 Large towns (pop. 20,000 – 30,000) 
 Mid-sized towns (pop. 5,000 – 20,000) 
 Small towns (pop. 1,500 – 5,000) 
 Villages (pop less than 1,500) 
 
 
47. Setting (Please tick one) 
 
 Town high street  
 Shopping centre 
 Housing estate 
 Among local neighbourhood shops (a small parade) 
 Other (please specify) ______________________________ 
 
 
48. How close is your pharmacy to the following healthcare services? 
 
 Proximity 
Service >500m 501m – 1km >1km 
Acute hospital    
Private urgent care centre    
GP surgery    
HSE health centre    
HSE primary care centre    
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50. Please tell us if the pharmacy ever opens: [Please tick all that apply] 
 
 Before 9am (Mon – Fri) 
 After 6pm (Mon – Fri) 
 After 8pm (Mon – Fri) 
 After 10pm (Mon – Fri) 
 After 2pm (Sat) 
 After 6pm (Sat) 
 On a Sunday 
 
 
51. Please provide a breakdown of your pharmacy’s patient profile. [Does not need to add up to 100%] 
 
Category Approximate percentage of 
patients 
Older patients (over 60) ______% 
Families with children under 12 ______% 
Younger patients (over 12, under 30) ______% 
Patients living in Residential Care 
settings (e.g. Nursing Homes) ______% 
 
 





53. Is there a consultation/counselling area in the pharmacy where you can talk to patients in private? 
 
 Yes   No 
 
 





54. Do you allow any other practitioners to run clinics or services from your pharmacy? 
 
 Yes   No 
 
 
54a. If yes, please give details of the practitioner and the services provided 
 
___________________________________________________________________ (free text) 
 
 
55. Do you have any involvement in local multi-professional group/s? 
 
 Yes   No 
 
 
55a. If yes, please give details of which group/s 
 
___________________________________________________________________ (free text) 
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56. Do you have any professional engagement with patient support group/s? 
 
 Yes   No 
 
 
56a. If yes, please give details of the group/s and types of engagement 
 
 Engagement 













advice to group 
___________________________ 
    
___________________________ 
    
___________________________ 
    
___________________________ 
    
___________________________ 
    
___________________________ 
    
___________________________ 
    
 
 
57. How do you view pharmacy practice in Ireland currently and how would you like to see pharmacy practice 














58. Thank you for your time in completing this survey. We would welcome any additional comments you may 
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Follow-up interviews 
 
We plan to interview approximately 30 pharmacists following this survey, in order to explore emerging issues in more 
detail. Please indicate if you would be happy for an interviewer from Horwath Bastow Charleton to contact you with more 
information about the interview: 
 
 Yes   No 
 
If yes, please put your name and preferred telephone/fax contact number here. This personal information will not be 











If you do not hear from us by 31
st






THANK YOU FOR YOUR TIME IN COMPLETING THIS QUESTIONNAIRE 
 
Please return the survey by post by 16
th
 July 2010 to: 
 
Vanya Sargent 
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CONSENT FORM, AND QUESTIONS 
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INFORMATION SHEET 
 
You are being invited to take part in an interview for this project, following on from your completion 
of the PSI questionnaire. Please read the following information carefully before deciding whether to 
participate or not. If you have any questions before you can decide, please contact us. Our details 
are given at the bottom of this sheet. 
 
What is this project about? 
 
The PSI is undertaking a study to review and provide an understanding of the nature and type of 
pharmacy services currently being delivered in Ireland. 
 
The project aims to provide baseline information to assist the PSI to: 
 understand the nature and scope of pharmacy practice in Ireland 
 identify the strengths and weaknesses in the current provision of pharmacy services 
 identify areas of best practice 
 support the development of pharmacy practice in Ireland 
 
Over 400 pharmacists have already completed the PSI questionnaire, and the results are currently 
being prepared. The aim of this second phase is to discuss these issues in more detail with 
community pharmacists. We have been asked by the PSI to explore pharmacists‟ perceptions and 
experiences of current pharmacy practice, and their ideas for future services. We would like to 
explore issues such as successes and barriers in service provision, and your thoughts about the 
resources that you have (including your premises and staff), and that you might like to have. 
 
Why have I been asked? 
 
We are asking a sample of community pharmacists who responded to the PSI survey to take part 
in this part of the project. We are aiming to recruit pharmacists from both urban and rural areas to 
participate. 
 
What would I need to do? 
 
We would like to do one telephone interview with you that will take 20-30 minutes. We would like to 
focus on the services provided in the pharmacy and the supporting aspects such as premises, 
workforce, and technology, along with some discussion about CPD (incorporating CE) and 
interprofessional relationships. 
 
If you agree to take part, you should complete the consent form with this sheet and return it to the 
evaluation team by fax to 01 662 5105 or by post to HBC, Marine House, Clanwilliam Court, Dublin 
2. Then one of the team will telephone you to make an appointment for the interview that suits you. 
 
We will ask you if we can record the interview on a digital sound recorder. This means that we do 
not have to take lots of notes during the interview, and can concentrate on the discussion, but you 
can opt not to be recorded or ask at any time for the recording to stop. 
 
Please note that no identifying information will be passed to the PSI in respect of individual 
pharmacies. All information about individual pharmacies and pharmacists will be kept confidential, 
and any quotes used in the resultant documentation will be fully anonymised. 
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CONSENT FORM 
 
PSI Baseline Study of Pharmacy Practice 2010: Follow-up Interview 
 
If you would be willing to take part in this interview, please complete the form below and return it to 
us by fax to 01 662 5105, by post to HBC, Marine House, Clanwilliam Court, Dublin 2, or by 
scanning and emailing to vanya.sargent@hbc.ie. Please keep a copy for your records 
 
**Please initial all the grey boxes in the grid, and complete the box below with your contact 
details, today’s date, and signature** 
 
1. I confirm that I have read and understood the information given to me about 
this interview, and have had the opportunity to ask questions. 
  
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason. 
  
3. I understand that the interview will be recorded on digital audio, and that the 
recording will be kept securely until the end of the evaluation. I can ask for the 
recording to stop at any time, during which time field notes will be taken. 
  
4. I understand that all information about me will be kept confidential, and that 
any quotes used in reports or papers will be anonymised. 
  




Preferred Contact Telephone Number: ………………………………………………………………. 
 
Best day(s) / time(s) to call this number: ………………………………………………………….. 
 
 




For Office Use: 
 I confirm that I have fully explained the purpose of the project and what is involved to 
 
 __________________________________________________  
 
 I have checked that the interviewee has a copy of this form together with the information sheet 
 
Interviewer’s signature: ……………………………………Date: …………………………. 
 
Interviewer’s Name: …………………………………………………………….……………….. 
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QUALITATIVE INTERVIEW QUESTIONS 
 






Has the work that you do changed in the last [5 years]? If so, how? 
 





How do you feel about the services that you currently provide in your pharmacy? 
 
 Which services work well? Which work less well? 
 
Are there services that you would you like to offer in the future? 
 
 What are your main reasons for considering these services?  
 
What types of services should pharmacy as a profession concentrate on in the future? 
 
 Who should pay for them? 
 
What do you feel are the barriers to providing more services? 
 
What would enable you to provide more services? 
 





Could you describe the catchment area where the pharmacy is situated? 
 
 e.g. on a range from 1 to 10, disadvantaged to affluent 
 
Do you plan, or would you like, to make changes to the premises in the future? 
 
 Will future services need changes to premises? 
 





How do you feel about the IT resources within your pharmacy? 
 
Do you see the need for any changes in the IT capability of your pharmacy in order to support the 
services that you provide / would like to provide? 
 
 What links would you like to see with data that other professionals hold about your patients? 
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What would you change about the staffing in your pharmacy, if you could? 
 
 
Would you like to have a better ratio of pharmacists to other staff?  
 
 From a workload point of view 
 
 From a professional interaction point of view 
 
Does the current staffing in your pharmacy reflect what is needed to allow for the development of 
professional services?  
 
 Which activities are delegated to other staff by the pharmacists? 
 
 Could more activities be delegated to other staff? 
 
 What are the barriers to pharmacists delegating appropriate activities to other staff? 
 
 
Education / CPD 
 
Do you feel equipped for current and future practice with the CPD (incorporating CE) activities 
available to you? 
 






How would you describe your professional relationship with local GPs and other healthcare 
professionals (prompt list to be included for interviewer, e.g., hospital pharmacists; public health 
nurses, etc.)? 
 
 What factors make for a successful professional relationship? 
 
 What barriers prevent a successful professional relationship/working together for patients’ 
benefit? 
 
 How can pharmacists support this? 
 




Is there anything else that you would like to say about pharmacy services in Ireland? 
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FRAMEWORK FOR PSI SCOPING EXERCISE 
 
Author / Citation of 
paper or report 























      
Pharmacy Guild of 
Australia, Australian 













pharmacies in the 









F/T, P/T, qualified 
Covers a wide 
variety of services, 
health care and 
other 
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Author / Citation of 
paper or report 












CG Berbatis, VB 
Sunderland, CR Mills 









School of Pharmacy, 
Curtin University of 
Science and 












to reflect adequate 
numbers of remote 
and rural 
pharmacies 
Gave some info 
















info, e.g., refused 
Rx for errors, 
fraud etc. 
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Author / Citation of 
paper or report 







































about uptake of 27 
enhanced services. 








at: Shop location, 
hours open, size, 
inclusion of a 
forward pharmacy 
area, inclusion of 
an enclosed 
counselling area, 
inclusion of an 
unenclosed 















(membership of a 
marketing 
or banner group of 
pharmacies) 
Most services 
seem to be paid 







(EPS) refers to a 
service 
implemented in 
pharmacies that is 
additional to or not 
routinely provided 
with prescribed or 
non-prescribed 
medicines. 





to the service and 
staff who are 
competent or 
formally trained 
and for which a 












Barrier to provision 
of enhanced 
services: cannot 
meet with GPs and 





to patient notes 
(AA – I presume 
technology is 
involved in this).  
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Author / Citation of 
paper or report 



















National evaluation of 








telephone survey of 
all community 
pharmacies in 31 
PCOs in England 
and Wales 
 
Does not report 
response rate – 
total sample was 
1080 pharmacies 
Three-quarters of 












One in three were 
planning staff 









provided by 87% 
of pharmacies 
(40% of which 
were providing 3 
















with respect from 
GPs 
Staff in 60% of 
pharmacies have 






advise the public 
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Author / Citation of 
paper or report 




















services and the new 
community pharmacy 









postal survey for all 
PCTs in England. 
 
74% response rate 
  Looked at the 




























service mix: evidence 









To describe mix of 
services offered and 
factors associated 
with offering them. 
Analysis of 2004 
workforce survey in 













Numbers of other 
staff 
Rx volume 
Provides list of 
services offered.  
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Author / Citation of 
paper or report 












Feletto E, Wilson LK, 






Flexibility in community 
pharmacy: a qualitative 
study of business 
models and cognitive 
services 
 
Pharmacy World and 
























Attitude of the 
pharmacy owners 









Owners choose a 
position most in 






changing the role 
















Health care solution 
pharmacies 
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Author / Citation of 
paper or report 












Abhijit S. Gadkari, MS; 
David A. Mott, PhD; 
David H. Kreling, PhD ; 
and Joseph K. 







Associated With the 
Provision of Drug 





The Journal of Rural 




Survey (2005) sent 
to manager/owner 
of all 279 non-
metropolitan 
community 
pharmacy sites in 
Wisconsin. Qs on 
 7 drug therapy 










the pharmacy sites 
and how DTS were 
provided. 
44% response rate  












to provision of any 
DTS. 
31% of the 
respondent 
pharmacies 
offered MTMS and 
31% offered DSM 
programs  
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in North Carolina 
community 
pharmacies: Current 
practice patterns and 
projected demand 
 









pharmacists in NC, 
USA 
 




   
Hughes CM, Hawwa 
AF, Scullin C, 
Anderson C, Bernsten 









 Pharmacy World and 
Science.  














Care Scale BPCS 
used. 
Response rates 
varied from 10.1% 
in Germany to 








(55.8% in Ireland)  
 





Higher number of 
pharmacist and 
dispensing staff 
linked to higher 
BPCS scores 
Services linked to 
domains within the 
BPCS – 
sometimes difficult 
to link them to 
specific services – 






at least one health 
service and BPCS 
scores 
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in Canada 2007: 






Survey – detail not 


















Lists top specialist 
services provided, 
and type of 
pharmacy most 
likely to provide 
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Practices Volume I - 
Moving Forward: 
Pharmacy Human 





























service. This is 
particularly true at 
the introduction of 
a new service, 
when staffing 
levels may be low, 
and economies of 
scale are not yet 
realized. In some 
cases, projects 
are victims of their 
own success and 
this situation 
results in an 
inability to provide 














involves taking on 




















the value of 
pharmacy 
services: This was 
an initial hurdle for 
most of the 
innovative practices 
that involved closer 
working 
relationships with 
other health care 
professionals. It 
was a barrier that 
was overcome, but 
it required effective 
communication with 
other professionals 
to demonstrate the 
capacity of the 
pharmacist and the 
benefits of an 


















forms of access. 
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descriptive report.  
 








types of patient care 
services that can be 
offered: “value-
added services that 























FTE staff data 
 
Gives range of 
„patient care‟ 
services provided 
(and how much 
they charged, if 
they did).  
Also asks about 
who provides the 





Discusses use of 
outside contractors 








The key role of sole 
community 




The North Carolina 
Rural Health Research 










  42% offered one 
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Alison S Roberts, SI 
Benrimoj, Timothy F 
Chen, Kylie A Williams 
and Parisa Aslani 
 







services in community 




























factors (see above 
article, also Roberts 
) 
























































+ives: use of 
new technology 
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Alison S Roberts, SI 
(Charlie) Benrimoj, 
Timothy F Chen, Kylie 
A Williams 
and Parisa Aslani 
 







services in community 
pharmacy: a review of 









As above, narrative 
review of 
conceptual & 
empirical lit, to 
identify facilitators 
to practice change. 
Range of potential 
facilitators 
identified, as 














as predictor & 
evaluative tool 








































who use their 
skills and 
knowledge to take 
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Type of pharmacy 
Work patterns of 
staff 
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Hynninen JT, Haikala 








in Finnish community 
pharmacies 
 
Pharmacy World and 






sectional survey of 
308 pharmacy 
owners and 373 
staff pharmacists 




about the future of 


















sales and stock 
holding 
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Zardain E, del Valle 
MO, Loza MI, Garcia 
E, Lana A, Markham 







determinants of the 
implementation of 
Pharmaceutical Care in 
Spain 
 
Pharmacy World and 
Science 31: 174-82 
 
lopez@uniovi.es 
Exploration of the 
implementation of 
pharmaceutical care 




Prochaska and Di 
Clemente‟s stages 
of change model, 









 Most pharmacists 
were in the pre-
contemplation 
stage for PC i.e. 
they did not plan 
to take on the new 
role. 
 
Only 11.8% were 




Only a further 6% 
of pharmacists 
were prepared to 












the likelihood of 
implementing PC. 





and was the best 






Odds ratio of 
undertaking PC 
was 14 times 
higher in the 
group receiving 
training. 
Pharmacists in the 
maintenance stage 



















NB – Many 
respondents 
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Identifying Significant Predictors of whether a Pharmacy 
Provides Enhanced Services or Would Like to 







Data were provided from a sample of 457 Pharmacies in Ireland where interest was in identifying 
those explanatory variables (of the eight provided) that were useful predictors of whether a 
Pharmacy already provides Enhanced Services or are willing to do so. 
 
Initially an analysis of the usefulness of each explanatory variable separately was performed (using 
the Chi square test or two sample t-test as appropriate).   Pharmacy Location, Type and % GMS 
Prescription Percentage were identified as potentially useful predictors of provision of Enhanced 
Services.  Location and Pharmacy Type and Pharmacists Age were identified as useful predictors 
of willingness to provide enhanced services.     
 
When considering factors that are likely to predict whether a Pharmacy, in the population of 
interest, provides Enhanced Services or Not Logistic Regression identified that Pharmacy Type is 
an important predictor with Pharmacies with 6 or more outlets twice as likely to provide enhanced 
services compared to Single Pharmacies with little difference between Pharmacies with 2-5 outlets 
and Single Pharmacies.  The Location of the Pharmacy is an important predictor also where 
Pharmacies in Midsized towns were identified as being half as likely to provide enhanced services 
compared to Pharmacies in Cities.  There was also a suggestion, based on using Classification 
Trees, that percentage of GMS Prescriptions may also be a useful predictor where a Pharmacy 
with less than 26% of GMS Prescriptions is more likely to Provide Enhanced Services. 
 
Logistic Regression identified that Younger Pharmacists (44 and younger) are more likely to be 
willing to provide enhanced services compared to older Pharmacists as are Pharmacies that are 
part of 2-5 outlets.  Classification Trees suggested that information relating to the percentage GMS 
prescriptions a Pharmacy has is important also with willingness to provide enhanced services 




Data were provided from 457 pharmacies. There were two response variables;  
 
1. Whether the Pharmacy Provides Enhanced Services 
2. Whether a Pharmacy Would Like to Provide Enhanced Services.   
 
Both responses were binary categorical variables (coded as Yes or No).  Complete data were 
available for each response.  Bar charts of the counts and percentages for each response variable 
are given in Figure 1 and Box 1 below. 
 
Box 1. 
Tally for Discrete Variables: Provide Enhanced, Would Like To Pr  
 
 Provide                    Would Like 
Enhanced                    To Provide 
Services  Count  Percent      Services  Count  Percent 
      No    246    53.83            No    110    24.07 
     Yes    211    46.17           Yes    347    75.93 
      N=    457                     N=    457 
 
Of the 457 Pharmacies in the study, 46% do provide enhanced services while 76% would like to. 
 
Figure 1. 
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Bar  Chart of Whether Enhanced Services are Provided Bar  Chart of Would Like T o Provide Services
 
 
The explanatory variables (i.e. variables that might be useful predictors of the response variables) 
are as follows: 
 
Care YN: Does this pharmacy provide services to patients in residential care settings?  
 




 How many prescription items are dispensed in the pharmacy in a typical month? [Please tick one] 
 
 Less than 500 
 501 – 1000 
 1,001 – 2,000 
 2,001 – 3,000 
 3,001 – 4,000 
 4,001 – 5,000 
 5,001 + 
 
 
Age: Which age group are you in? 
 
  Under 35 
  35-44 
  45-54 
  55-64 
  65 and over 
 
 









PharType: Type of pharmacy (Please tick one) 
 
 Single outlet 
 Group or Chain ownership with 2-5 outlets 
 Group or Chain ownership with 6 or more outlets 
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Location (Please tick one) 
 
 City (pop greater than 30,000) 
 Large towns (pop. 20,000 – 30,000) 
 Mid-sized towns (pop. 5,000 – 20,000) 
 Small towns (pop. 1,500 – 5,000) 
 Villages (pop less than 1,500) 
 
Please indicate how satisfied you are with your professional relationship with local doctors for the 
purpose of providing patient care. 
 
Circle a number where 1 is very dissatisfied and 5 is very satisfied 
 
1 2 3 4 5 
 
A small percentage of missing data was prevalent in several of the explanatory variables as 





Tally for Discrete Variables: Care YN  
 
CareYN  Count  Percent 
     *     23     5.03 
    No    292    63.89 
   Yes    142    31.07 
    N=    457 
 
 
Tally for Discrete Variables: Age  
 
        Age  Count  Percent 
   Under 35    176    38.51 
      35-44    158    34.57 
      45-54     81    17.72 
      55-64     28     6.13 
65 and over     10     2.19 
          *      4     0.88 
         N=    457 
 
  
Tally for Discrete Variables: DrSatis_1  
 
                         DrSatis_1  Count  Percent 
                 Very Dissatisfied     19     4.16 
                      Dissatisfied     32     7.00 
Neither Satisfied nor Dissatisfied    119    26.04 
                         Satisfied    147    32.17 
                    Very Satisfied    129    28.23 
                                 *     11     2.41 
                                N=    457 
 
 
Tally for Discrete Variables: PharType  
 
                                       PharType  Count  Percent 
                                  Single outlet    233    50.98 
      Group or chain ownership with 2-5 outlets    118    25.82 
Group or chain ownership with 6 or more outlets     97    21.23 
                                              *      9     1.97 
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Tally for Discrete Variables: Locatn  
 
                                Locatn  Count  Percent 
       Villages (pop. less than 1,500)     51    11.16 
     Small towns (pop. 1,500 to 5,000)    103    22.54 
Mid-sized towns (pop. 5,000 to 20,000)    105    22.98 
   Large towns (pop. 20,000 to 30,000)     68    14.88 
       City (pop. greater than 30,000)    121    26.48 
                                     *      9     1.97 
                                    N=    457 
 
Summary statistics for the continuous explanatory variables are displayed in Box 3, where again 
missing data are represented by an asterisk.  Note that 15% (i.e.68/454) of the data were missing 
for the Total Prescriptions variable. 
Box 3. 
Descriptive Statistics: Total Prescripti, Percentage of GM, Number of Pharma  
 
Variable                    N  N*    Mean  SE Mean   StDev  Minimum      Q1 
Total Prescriptions       389  68    4266      127    2510      100    2404 
Percentage of GMS Prescr  389  68  62.513    0.804  15.850   12.460  53.210 
Number of Pharmacists     454   3  2.0738   0.0346  0.7381   1.0000  2.0000 
 
Variable                  Median      Q3  Maximum 
Total Prescriptions         3958    5635    16320 
Percentage of GMS Prescr  65.730  74.290  100.000 
Number of Pharmacists     2.0000  2.0000   5.0000 
 
As the variable representing the Number of Pharmacists is discrete a tally of the frequency is 
displayed also (Box 4).  Note that several of the Pharmacies listed ½ time positions. 
 
Box 4. 
Tally for Discrete Variables: Number of Pharmacists  
 
  Number of 
Pharmacists  Count  Percent 
        1.0     87    19.16 
        1.5      3     0.66 
        2.0    260    57.27 
        2.5      2     0.44 
        3.0     84    18.50 
        4.0     17     3.74 
        5.0      1     0.22 
         N=    454 
         *=      3 
 
Initially an analysis of the relationship between each explanatory variable separately and the 
responses was performed to identify which of the explanatory variables might be useful predictors 
of whether a Pharmacy already provides enhanced services or indeed whether a Pharmacy is 
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1.  Provide Enhanced Services 
 
Analysing the relationship between each Explanatory individually and the Response 
variables. 
 
Bar charts and tables of the frequency (and %) of each categorical explanatory variable against the 
response variables are given in the appendix.  For ease of interpretation the table of the 
frequencies of those Providing Services to Patients in Residential Care settings is also given in 
Box 5 below.   
 
Box 5. 
Tabulated statistics: CareYN, Provide Enhanced Services  
 
Rows: CareYN   Columns: Provide Enhanced Services 
 
          No    Yes     All 
 
*         12     11      23 
       52.17  47.83  100.00 
 
No       157    135     292 
       53.77  46.23  100.00 
 
Yes       77     65     142 
       54.23  45.77  100.00 
 
All      246    211     457 
       53.83  46.17  100.00 
 
Cell Contents:      Count 
                    % of Row 
 
There were comparable proportions (approximately 46% highlighted in bold) providing enhanced 
services for pharmacies that do and do not provide care in residential settings.   
 
The Chi-squared test was used in order to identify those variables where there was evidence that 
the difference in the sample proportions reported might be large enough to represent an actual 
difference in the population of pharmacists from which the sample was taken. The only variables 
identified as exhibiting a difference in sample proportions that may be reflective of a real effect in 
the population were the Type of Pharmacy (p<0.001) and the Location of the Pharmacy (p=0.03).     
 
The significant association identified for the Type of Pharmacy was due to the fact that the sample 
proportion Providing Enhanced Services was comparable for both Single (41%) and Group or 
Chain Ownership with 2 Pharmacies (42%) but was considerably higher (64%) for Group or Chain 
Ownership with 6 Pharmacies.   
 
The significant association identified for Pharmacy Location was due to the fact that the sample 
proportions Providing Enhanced Services increased with increasing Location size i.e. from 39% in 
Village Pharmacies to 56% in City Pharmacies.   
 
As the p-value was greater than 0.05 for all other categorical explanatory variable the data are 
consistent with there being no association between these variables and whether a Pharmacy is 
Providing Enhanced Services in the population of interest and any difference noted in the sample 
proportions is likely to be due to sample variation alone. 
 
Boxplots and summary statistics of the sample distribution of the continuous explanatory variables, 
namely number of Pharmacists employed and the % of GMS Prescriptions by whether Enhanced 
Services are Provided are given in Figure 2. 
 
Figure 2. 
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The distribution of Total Prescriptions looks comparable for Pharmacies that do and do not 
provided enhanced services.  Although the sample mean was slightly higher for those providing 
enhanced services a two sample t-test did not provide any evidence of a difference in the mean 
Total Prescriptions (p=0.264) in the population suggesting that Total Prescriptions is unlikely to be 
a useful predictor of whether enhanced services are provided or not.   
 
Box 6. 
Descriptive Statistics: Total Prescriptions  
 
                     Provide 
                     Enhanced 
Variable             Services    N  N*  Mean  SE Mean  StDev  Minimum    Q1 
Total Prescriptions  No        207  39  4132      172   2471      227  2282 
                     Yes       182  29  4418      189   2552      100  2780 
 
                     Provide 
                     Enhanced 
Variable             Services  Median    Q3  Maximum 
Total Prescriptions  No          3713  5510    15100 
                     Yes         4015  5828    16320 
 
Although the overall distribution of the Percentage of GMS Prescriptions looks comparable for 
Pharmacies that do and do not provided enhanced services (Figure 3).  The summary statistics 
identify a 5% smaller percentage in GMS Prescriptions in Pharmacies providing Enhanced 
Services (Box 7). One the basis of a two sample t-test this difference was identified as significant 
(p=0.01) and it is estimated the likely difference in the population is somewhere between 1 and 7 
percent.  This suggests that GMS prescriptions may be a useful predictor of whether a Pharmacy 





























Boxplot of Total Prescriptions
by Whether Would Like to Provide Enhanced Services
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Descriptive Statistics: Percentage of GMS Prescriptions  
 
                          Provide 
                          Enhanced 
Variable                  Services    N  N*    Mean  SE Mean   StDev  Minimum 
Percentage of GMS Prescr  No        207  39  64.494    0.952  13.696   26.490 
                          Yes       182  29   60.26     1.32   17.76    12.46 
 
                          Provide 
                          Enhanced 
Variable                  Services      Q1  Median      Q3  Maximum 
Percentage of GMS Prescr  No        55.300  66.800  74.800   93.030 
                          Yes        50.67   62.81   73.35   100.00 
 
 
Analysing the relationship between the Explanatory variables collectively and the Response 
variables. 
 
The next step in the analysis is to model the relationship between the explanatory variables 
collectively as there may be useful predictive information when considering the variables 
collectively and indeed when variables interact with each other. 
 
As the response variables are binary the two approaches considered are Logistic Regression and 
Classification Trees.  The former approach is presented first.  In this approach the odds of a 
Pharmacy providing enhanced services is modelled as a function of the explanatory variables 
where the main aim is to identify the minimally useful subset of explanatory variables.  Initially a full 
model (i.e. including all explanatory variables and their interactions) were fitted.  Variable selection 
procedures were then used to identify which variables can be dropped from the model as deemed 
unnecessary. 
 
Output from all models fitted are included in the appendix.  The final (i.e. most useful) model, 



















Boxplot of Percentage of GMS Prescriptions
by Whether Would Like to Provide Enhanced Services
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Box 8. 
                                                            
                             Odds     95% CI 
Predictor                                             P  Ratio  Lower  Upper 
Constant                                          0.956 
 
PharType (Single as Baseline) 
 Group or chain ownership with 2-5 outlets        0.897   0.97   0.61   1.53 
 Group or chain ownership with 6 or more outlets  0.001   2.41   1.43   4.04 
 
Location  (City as Baseline) 
 Large towns (pop. 20,000 to 30,000)              0.924   1.03   0.56   1.90 
 Mid-sized towns (pop. 5,000 to 20,000)           0.021   0.53   0.30   0.91 
 Small towns (pop. 1,500 to 5,000)                0.084   0.61   0.35   1.07 
 Villages (pop. less than 1,500)                  0.124   0.58   0.29   1.16 
 
Two variables were identified as significantly useful predictors from the complete set of explanatory 
variables available in this analysis.  These variables were Pharmacy Type and Location. 
 
From the output displayed in Box 8, Pharmacies with 6 or more are 2.45 times more likely to 
provide enhanced services compared to Single pharmacies with no difference identified in the odds 
for Pharmacies with 2 or more compared to Single Pharmacies. A bar chart of the percentages 
providing enhanced services by Pharmacy (Figure 4) highlights this result where comparably 
higher proportions do not provide enhanced services in Single and Chains with 2-5 outlets while in 
















































































Bar Chart of Provide Enhanced Services by Pharmacy Type
 
 
When considering Location, using Cities as a baseline for comparison, Pharmacies in Midsized 
towns were identified as being half as likely (i.e. and Odds Ratio of 0.5) to provide enhanced 
services compared to Pharmacies in Cities with no other level of this variable identified as differing 
from Cities.  
 
A plot of this Location by Enhanced Services provision (Figure 5) helps understand what this 
finding may represent.  A higher proportion of Pharmacies located in a City offered enhanced 
services while in all other locations pharmacies tended not to provide enhanced services.   
 
Figure 5. 
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Bar Chart of Location by Provide Enhanced Services
 
 
The level representing Small Towns was close to being significant (p=0.08) however.  The reason 
that only the Mid Sized Towns category was identified as significant when compared to Cities is 
probably due to sample size (Box 9) as there were nearly double the amount of Pharmacies in Mid 
and Small Towns compared to Villages. 
 
Box 9. 
Tabulated statistics: Locatn, Provide Enhanced Services  
 
Rows: Locatn   Columns: Provide Enhanced Services 
 
                                    No  Yes  All 
 
Villages (pop. less than 1,500)     31   20   51 
Small towns (pop. 1,500 to 5,00     62   41  103 
Mid-sized towns (pop. 5,000 to      62   43  105 
Large towns (pop. 20,000 to 30,     31   37   68 
City (pop. greater than 30,000)     53   68  121 
*                                    7    2    9 
All                                246  211  457 
 
Cell Contents:      Count 
 
Despite the univariate analysis suggesting that the percentage of GMS prescriptions may be a 
useful predictor, this variable was not significant in the model already containing Pharmacy Type 
and Location.   This suggests that the information provided by the GMS prescriptions variable is 
already contained in the information provided by Pharmacy Type and Location and is therefore 
redundant once information on these variables is available.  The reason for this is that it is likely 
that the GMS prescriptions variable is likely to be correlated with both Pharmacy Type and 
Location. 
 
The second approach considered involved fitting Classification Trees to uncover structure in the 
sample provided that may be reflective of real effects in the population of pharmacies of interest.  
Tree based procedures should be interpreted with care however as they are data driven 
approaches and all results uncovered should be considered as exploratory. 
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Trees were fit and pruned using Recursive Partitioning, Chi Square Automatic Interaction Detection 
and Conditional Trees approaches and the best tree, in terms of minimum misclassification error, is 
presented in Figure 6. 
 
Figure 6. 
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The tree identified Percent GMS Prescriptions as the most useful variable when categorising it as a 
binary variable with a cut-point of above and below 26%. The reason behind this split is clear when 
looking at the predicted categories at the terminal node for those pharmacies with ≤26% GMS 
Prescriptions; all provided enhanced services!   Of those with >26% GMS Prescriptions the next 
most useful variable was Pharmacy Type with Group of 6+ deemed different from all other Types 
and no other information was needed for this cohort.  For Group Pharmacies with 2 to 5 or Single 
Pharmacies Location was identified as a useful predictor with relationship with local doctors a 
useful predictor for pharmacies from larger locations.  The predicted proportions of those that are 
and are not providing enhanced services are given at each terminal node so that a comparison can 
be made between Pharmacy characteristics.   For example the pathway leading to lowest 
proportion providing enhanced services is Node 8 where 80% of pharmacies following this pathway 
did not provide enhanced services.  These pharmacies had higher GMS prescriptions, smaller 
pharmacies in large towns or cities with poor relationships with local doctors. 
 
2. Willing to Provide Enhanced Services 
 
The second response variable of interest is whether a Pharmacy would like to provide enhanced 
services. Once again the initial analysis presented is one that considers each explanatory variable 
separately in order to identify potentially useful predictors. 
 
Analysing the relationship between each Explanatory individually and the Response 
variables. 
 
Two of the categorical explanatory variables were identified as potentially useful significant 
predictors, namely Type of Pharmacy (p<0.001) and Age Group (p=0.02) of the Pharmacists who 
filled out the survey.  Neither of the two continuous explanatory (i.e. Total Prescriptions and 
Percentage of GMS Prescriptions) were identified as useful predictors as there was no evidence of 
a difference in the mean for each between those Pharmacies that would like to provide enhanced 
services and those Pharmacies that don‟t (p=0.20 and p=0.23 respectively). 
 
For brevity only results relating to Type of Pharmacy and Age are presented here while all other 
tables of each categorical explanatory variable and summary statistics for the two continuous 
explanatory variables are given in the appendix.   
 
The majority of the Pharmacists would like to provide more enhanced services however the 
proportions within Pharmacy Type differs with the largest proportion evident in the Group 












































































Chart of Pharmacy Type, Would Like To Provide Services
 
 
There is evidence that the younger pharmacists, namely those in the Under 35 and 35-44 age 
groups are more willing to provide enhanced services compared to older pharmacists (Figure 8). 
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Logistic regression models were fitted initially including all explanatory variables and two and three 
way interactions.  Terms were dropped from the model sequentially based on model diagnostics 
and goodness of fit measures until the model retaining only terms that were significant was 




                                                          Odds     95% CI 
Predictor                                             P  Ratio  Lower  Upper 
Constant                                          0.000 
 
PharType (Single as Baseline) 
 Group or chain ownership with 2-5 outlets        0.004   2.68   1.36   5.29 
 Group or chain ownership with 6 or more outlets  0.015   0.50   0.28   0.87 
 
Age  (Under 35 as Baseline) 
 35-44                                            0.286   0.73   0.41   1.31 
 45-54                                            0.003   0.37   0.19   0.71 
 55-64                                            0.054   0.40   0.16   1.02 
 65 and over                                      0.010   0.17   0.04   0.65 
 
The Odds Ratios (and corresponding p-values) suggest that Group Pharmacies with 2-5 outlets 
are nearly 3 times (i.e. 2.68) more likely while Group Pharmacies with 6 or more outlets are about 
half as likely (Odds Ratio of 0.50) to want to Provide Enhanced Services compared to Single 
Pharmacies in the population of Pharmacies of interest.   
 
There was a clear age effect where the older pharmacists were much less willing to provide 
enhanced services compared to those under 44.  In particular there was no significant difference 
between those younger than 35 and aged 35-44 in terms of being willing to provide enhanced 
services but those aged 45-54 were significantly less likely (Odds Ratio=0.37) as were those 55-64 
(Odds Ratio 0.40) and those aged 65 and over (Odds Ratio 0.17) compared to the young 
pharmacists.  
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These results suggest that whether a Pharmacies is part of a group of 2-5 units and contains 
younger pharmacists are good predictors of willingness to provide enhanced services. 
 
The Tree based approach identified the same predictors as the Logistic Model but did identify 
Percentage of GMS Prescriptions, with a three way split (<40%, 40-76%, >76%), as being a useful 
predictor.  The Group Pharmacies of 2-5 outlets were again identified as having a high proportion 
willing to provide enhanced services (90%).   
 
As the Percentage of GMS Prescriptions increased so too did the willingness to provide enhanced 
services.   
 
The same effect of Age Groups was evident (i.e. younger versus older) however Age was only 
identified as being a useful predictor in Single or Group Pharmacies of 6 with either having greater 
than 76% GMS Prescriptions.   
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Figure 9. 
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Conclusion  
 
When considering factors that are likely to predict whether a Pharmacy, in the population of 
interest, provides Enhanced Services or Not the Pharmacy Type is an important predictor with 
Pharmacies with 6 or more outlets than twice as likely to provide enhanced services compared to 
Single Pharmacies with little difference between Pharmacies with 2-5 outlets and Single 
Pharmacies.  The Location of the Pharmacy is an important predictor also where Pharmacies in 
Midsized towns were identified as being half as likely to provide enhanced services compared to 
Pharmacies in Cities.  There was also a suggestion that a Pharmacy with less than 26% of GMS 
Prescriptions is more likely to Provide Enhanced Services. 
 
Younger Pharmacists (44 and younger) are more likely to be willing to provide enhanced services 
compared to older Pharmacists as are Pharmacies that are part of 2-5 outlets.  There was a 
suggestion that information relating to the percentage GMS prescriptions a Pharmacy has is 
important also with willingness to provide enhanced services increasing with increasing percentage 
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Appendix: 
 
Tabulated statistics: CareYN, Provide Enhanced Services  
 
Rows: CareYN   Columns: Provide Enhanced Services 
 
          No    Yes     All 
 
*         12     11      23 
       52.17  47.83  100.00 
 
No       157    135     292 
       53.77  46.23  100.00 
 
Yes       77     65     142 
       54.23  45.77  100.00 
 
All      246    211     457 
       53.83  46.17  100.00 
 
Cell Contents:      Count 




Tabulated statistics: Age, Provide Enhanced Services  
 
Rows: Age   Columns: Provide Enhanced Services 
 
                  No    Yes     All 
 
Under 35          91     85     176 
               51.70  48.30  100.00 
 
35-44             84     74     158 
               53.16  46.84  100.00 
 
45-54             49     32      81 
               60.49  39.51  100.00 
 
55-64             15     13      28 
               53.57  46.43  100.00 
 
65 and over        6      4      10 
               60.00  40.00  100.00 
 
*                  1      3       4 
               25.00  75.00  100.00 
 
All              246    211     457 
               53.83  46.17  100.00 
 
Cell Contents:      Count 
                    % of Row 
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Tabulated statistics: DrSatis_1, Provide Enhanced Services  
 
Rows: DrSatis_1   Columns: Provide Enhanced Services 
 
                                      No    Yes     All 
 
Very Dissatisfied                     11      8      19 
                                   57.89  42.11  100.00 
 
Dissatisfied                          19     13      32 
                                   59.38  40.63  100.00 
 
Neither Satisfied nor Dissatisf       65     54     119 
                                   54.62  45.38  100.00 
 
Satisfied                             74     73     147 
                                   50.34  49.66  100.00 
 
Very Satisfied                        68     61     129 
                                   52.71  47.29  100.00 
 
*                                      9      2      11 
                                   81.82  18.18  100.00 
 
All                                  246    211     457 
                                   53.83  46.17  100.00 
 
Cell Contents:      Count 
                    % of Row 
 
Tabulated statistics: Number of Pharmacists, Provide Enhanced Services  
 
Rows: Number of Pharmacists   Columns: Provide Enhanced Services 
 
              No    Yes    All 
 
1.0           51     36     87 
            58.6   41.4  100.0 
 
1.5            3      0      3 
           100.0    0.0  100.0 
 
2.0          136    124    260 
            52.3   47.7  100.0 
 
2.5            0      2      2 
             0.0  100.0  100.0 
 
3.0           43     41     84 
            51.2   48.8  100.0 
 
4.0           10      7     17 
            58.8   41.2  100.0 
 
5.0            1      0      1 
           100.0    0.0  100.0 
 
Missing        2      1      * 
               *      *      * 
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All          244    210    454 
            53.7   46.3  100.0 
 
Cell Contents:      Count 




Tabulated statistics: PharType, Provide Enhanced Services  
 
Rows: PharType   Columns: Provide Enhanced Services 
 
                                      No    Yes     All 
 
Single outlet                        138     95     233 
                                   59.23  40.77  100.00 
 
Group or chain ownership with 2       69     49     118 
                                   58.47  41.53  100.00 
 
Group or chain ownership with 6       35     62      97 
                                   36.08  63.92  100.00 
 
*                                      4      5       9 
                                   44.44  55.56  100.00 
 
All                                  246    211     457 
                                   53.83  46.17  100.00 
 
Cell Contents:      Count 




Tabulated statistics: Locatn, Provide Enhanced Services  
 
Rows: Locatn   Columns: Provide Enhanced Services 
 
                                      No    Yes     All 
 
Villages (pop. less than 1,500)       31     20      51 
                                   60.78  39.22  100.00 
 
Small towns (pop. 1,500 to 5,00       62     41     103 
                                   60.19  39.81  100.00 
 
Mid-sized towns (pop. 5,000 to        62     43     105 
                                   59.05  40.95  100.00 
 
Large towns (pop. 20,000 to 30,       31     37      68 
                                   45.59  54.41  100.00 
 
City (pop. greater than 30,000)       53     68     121 
                                   43.80  56.20  100.00 
 
*                                      7      2       9 
                                   77.78  22.22  100.00 
 
All                                  246    211     457 
                                   53.83  46.17  100.00 
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Cell Contents:      Count 
                    % of Row 
 
Would Like to Provide: 
 
Tabulated statistics: CareYN, Would Like To Provide Services  
 
Rows: CareYN   Columns: Would Like To Provide Services 
 
          No    Yes     All 
 
*          6     17      23 
       26.09  73.91  100.00 
 
No        72    220     292 
       24.66  75.34  100.00 
 
Yes       32    110     142 
       22.54  77.46  100.00 
 
All      110    347     457 
       24.07  75.93  100.00 
 
Cell Contents:      Count 




Tabulated statistics: Age, Would Like To Provide Services  
 
Rows: Age   Columns: Would Like To Provide Services 
 
                   No    Yes     All 
 
Under 35           32    144     176 
                18.18  81.82  100.00 
 
35-44              33    125     158 
                20.89  79.11  100.00 
 
45-54              27     54      81 
                33.33  66.67  100.00 
 
55-64               9     19      28 
                32.14  67.86  100.00 
 
65 and over         5      5      10 
                50.00  50.00  100.00 
 
*                   4      0       4 
               100.00   0.00  100.00 
 
All               110    347     457 
                24.07  75.93  100.00 
 
Cell Contents:      Count 
                    % of Row 
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Tabulated statistics: DrSatis_1, Would Like To Provide Services  
 
Rows: DrSatis_1   Columns: Would Like To Provide Services 
 
                                      No    Yes     All 
 
Very Dissatisfied                      5     14      19 
                                   26.32  73.68  100.00 
 
Dissatisfied                           7     25      32 
                                   21.88  78.13  100.00 
 
Neither Satisfied nor Dissatisf       33     86     119 
                                   27.73  72.27  100.00 
 
Satisfied                             31    116     147 
                                   21.09  78.91  100.00 
 
Very Satisfied                        28    101     129 
                                   21.71  78.29  100.00 
 
*                                      6      5      11 
                                   54.55  45.45  100.00 
 
All                                  110    347     457 
                                   24.07  75.93  100.00 
 
Cell Contents:      Count 




Tabulated statistics: PharType, Would Like To Provide Services  
 
Rows: PharType   Columns: Would Like To Provide Services 
 
                                      No    Yes     All 
 
Single outlet                         61    172     233 
                                   26.18  73.82  100.00 
 
Group or chain ownership with 2       12    106     118 
                                   10.17  89.83  100.00 
 
Group or chain ownership with 6       34     63      97 
                                   35.05  64.95  100.00 
 
*                                      3      6       9 
                                   33.33  66.67  100.00 
 
All                                  110    347     457 
                                   24.07  75.93  100.00 
 
Cell Contents:      Count 
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Tabulated statistics: Locatn, Would Like To Provide Services  
 
Rows: Locatn   Columns: Would Like To Provide Services 
 
                                      No    Yes     All 
 
Villages (pop. less than 1,500)       11     40      51 
                                   21.57  78.43  100.00 
 
Small towns (pop. 1,500 to 5,00       27     76     103 
                                   26.21  73.79  100.00 
 
Mid-sized towns (pop. 5,000 to        19     86     105 
                                   18.10  81.90  100.00 
 
Large towns (pop. 20,000 to 30,       15     53      68 
                                   22.06  77.94  100.00 
 
City (pop. greater than 30,000)       36     85     121 
                                   29.75  70.25  100.00 
 
*                                      2      7       9 
                                   22.22  77.78  100.00 
 
All                                  110    347     457 
                                   24.07  75.93  100.00 
 
Cell Contents:      Count 


















Bar Chart of Whether Would Like to Provide Enhanced Services
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Paneled by Whether Services are Provided to Residential Care Settings
Bar Chart of Whether Would Like to Provide Enhanced Services
* Missing Data
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Dissatisfied Neither Satisfied nor Dissatisfied
Satisfied Very Satisfied *
Bar Chart of Whether Would Like to Provide Enhanced Services






















Group or chain ownership with 2-5 outlets
Group or chain ownership with 6 or more outlets *
* Missing Data
Bar Chart of Whether Would Like to Provide Enhanced Services
Paneled by Pharmacy Size
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Villages (pop. less than 1,500)







Small towns (pop. 1,500 to 5,000) Mid-sized towns (pop. 5,000 to 20,000)
Large towns (pop. 20,000 to 30,000) City (pop. greater than 30,000) *
* Missing Data
Paneled by Location























55-64 65 and over *
* Missing Data
Paneled by Age Category of Pharmacy Respondent
Chart of Whether Would Like to Provide Enhanced Services
 PSI Baseline Study Final Report 




















Would Like To Provide Services
Percentage of GMS Prescriptions
Boxplot of Total Prescriptions, Percentage of GMS Prescriptions
 
 
Two-Sample T-Test and CI: Total Prescriptions, Would Like To Provide 
Services  
 




Services      N  Mean  StDev  SE Mean 
No           88  4615   3083      329 
Yes         301  4164   2313      133 
 
 
Difference = mu (No) - mu (Yes) 
Estimate for difference:  452 
95% CI for difference:  (-251, 1154) 
T-Test of difference = 0 (vs not =): T-Value = 1.27  P-Value = 0.205  DF 
= 117 
 
Two-Sample T-Test and CI: Percentage of GMS Prescr, Would Like To Provide 
Se  
 




Services      N  Mean  StDev  SE Mean 
No           88  60.4   19.6      2.1 
Yes         301  63.1   14.6     0.84 
 
 
Difference = mu (No) - mu (Yes) 
Estimate for difference:  -2.70 
95% CI for difference:  (-7.16, 1.75) 
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